[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 402
1. McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ: The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer; 2010 Mar 2;102(5):810-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).
  • BACKGROUND: Gestational trophoblastic neoplasia (GTN) after a hydatidiform mole is either treated with single- or multi-agent chemotherapy determined by a multifactorial scoring system.
  • Women with human chorionic gonadotrophin (hCG) levels >100 000 IU l(-1) can remain within the low-risk/single-agent category and usually choose one drug therapy.
  • Here we compare the success and duration of single- vs multi-agent chemotherapy in this patient group.
  • METHODS: Between 1980 and 2008, 65 women had a pre-treatment hCG >100 000 IU l(-1) and were low risk.
  • The initial hCG level, treatment regimens, changes and duration and overall survival were recorded.
  • RESULTS: Of 37 patients starting low-risk/single-agent treatment, 11 (29.7%) were treated successfully, whereas 26 (70.3%) required additional multi-agent chemotherapy to achieve complete remission (CR).
  • Combination chemotherapy was initially commenced in 28 women, and 2 (7%) required additional drugs for CR.
  • The overall duration of therapy for those commencing and completing single- or multi-agent chemotherapy was 130 and 123 days (P=0.78), respectively.
  • The median-treatment duration for patients commencing single-agent but changing to multi-agent chemotherapy was 13 days more than those receiving high-risk treatment alone (136 vs 123 days; P=0.07).
  • All 3 patients with an initial hCG >400 000 IU l(-1) and treated with single-agent therapy developed drug resistance.
  • CONCLUSION: Low-risk post-molar GTN patients with a pre-treatment hCG >100 000 and <400 000 IU l(-1) can be offered low-risk single-agent therapy, as this will cure 30%, is relatively non-toxic and only prolongs treatment by 2 weeks if a change to combination agents is required.
  • Patients whose hCG is >400 000 IU l(-1) should receive multi-agent chemotherapy from the outset.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / blood. Gestational Trophoblastic Disease / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Staging. Pregnancy. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(4):854-9 [10673528.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):204-7 [15262143.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1838-44 [11919242.001]
  • [Cites] J Reprod Med. 2004 Aug;49(8):643-54 [15457855.001]
  • [Cites] Cancer. 1976 Sep;38(3):1373-85 [182354.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2024-7 [6290020.001]
  • [Cites] Tumori. 1987 Jun 30;73(3):309-13 [3037744.001]
  • [Cites] Gynecol Oncol. 1988 Nov;31(3):439-44 [2846414.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Jul;96(7):795-802 [2548568.001]
  • [Cites] Br J Obstet Gynaecol. 1991 Jun;98(6):550-7 [1651757.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(6):461-5 [7514124.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2769-73 [8874338.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1204-7 [9849480.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):423-9 [15581942.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2005 Apr;45(2):161-4 [15760322.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):251-2; author reply 252-3 [16137746.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1432-8 [16803542.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):486-91 [17762576.001]
  • [Cites] BMJ. 2008;337:a1193 [18708429.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1578-83 [18453518.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Oct;103(1):33-7 [18632105.001]
  • [Cites] Lancet. 2000 Jul 1;356(9223):36-9 [10892763.001]
  • (PMID = 20160727.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Other-IDs] NLM/ PMC2833242
  •  go-up   go-down


2. Sempau L, Alonso-Alonso T, González-Morán A, Prada C, Lamoca-Martín M, Rodríguez-Prieto MA: [A new case of nevus oligemicus]. Dermatol Online J; 2010;16(8):16
Hazardous Substances Data Bank. LISINOPRIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A new case of nevus oligemicus].
  • [Transliterated title] Un nuevo caso de nevus oligemicus.
  • Nevus oligemicus is a rare lesion characterized by selective vasoconstriction of the deep dermal vascular plexus compared with the superficial one.
  • It has been suggested that it may be caused by increased sympathetic tone in the deep dermal vascular plexus or an abnormality of hormone receptors, which is why it is considered a functional nevus.
  • Clinically, it presents as an asymptomatic, fixed, livid erythematous macule with a striking decrease in local temperature compared with surrounding healthy skin.
  • Measurement of the surface temperature of the patch revealed a decrease of up to 2.5 degrees C with respect to surrounding skin.
  • The fixed nature of the lesions, consistent histopathology, and the finding of localized hypothermia allowed the diagnosis of nevus oligemicus.
  • Our case is the eleventh case of nevus oligemicus reported in the literature.
  • [MeSH-major] Nevus / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antihypertensive Agents / therapeutic use. Humans. Hypertension / drug therapy. Lisinopril / therapeutic use. Male. Prostatic Hyperplasia / diagnosis. Sulfonamides / therapeutic use

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804693.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Sulfonamides; 56211-40-6 / torsemide; E7199S1YWR / Lisinopril
  •  go-up   go-down


3. Blagden SP, Foskett MA, Fisher RA, Short D, Fuller S, Newlands ES, Seckl MJ: The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. Br J Cancer; 2002 Jan 7;86(1):26-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours.
  • Little literature exists on the safety of early pregnancy following chemotherapy.
  • Here we assess the rate of relapse and foetal outcome in women who have completed single and multi-agent chemotherapy for gestational trophoblastic tumours.
  • Patients were defined as receiving single agent or multi-agent treatment.
  • Relapse rates and foetal outcome were reviewed in the 230 patients who became pregnant within 12 months of completing chemotherapy.
  • Outcomes of 230 early pregnancies: 164 (71%) delivered at full term, 35 (15%) terminations, 26 (11%) spontaneous abortions, three (1.3%) new hydatidiform moles and two (1%) stillbirths.
  • Patients in either group who conceive within 12 months of completing chemotherapy are not at increased risk of relapse.
  • Though, we still advise avoiding pregnancy within 12 months of completing chemotherapy, those that do conceive can be reassured of a likely favourable outcome.
  • [MeSH-major] Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Abortion, Spontaneous / etiology. Adolescent. Adult. Congenital Abnormalities / etiology. Female. Fetal Death / etiology. Humans. Middle Aged. Neoplasm Recurrence, Local. Pregnancy. Retrospective Studies

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 May;18(10):2187 [10811687.001]
  • [Cites] Am J Obstet Gynecol. 1988 Mar;158(3 Pt 1):538-45 [3348314.001]
  • [Cites] Lancet. 2000 Jul 1;356(9223):36-9 [10892763.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):288-92 [10985882.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6):678-85 [11130475.001]
  • [Cites] Adv Cancer Res. 1975;22:57-155 [766582.001]
  • [Cites] Ann Intern Med. 1980 Jul;93(1):109-14 [6994532.001]
  • [Cites] Blood. 1981 Dec;58(6):1203-12 [6946847.001]
  • [Cites] Fertil Steril. 1982 Oct;38(4):447-53 [7117572.001]
  • [Cites] Lancet. 1983 May 21;1(8334):1126-7 [6133154.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1838-44 [2462026.001]
  • [Cites] Oncology (Williston Park). 1994 Jan;8(1):53-60; discussion 63-4, 67 [8123449.001]
  • [Cites] Hum Reprod. 1996 Feb;11(2):406-12 [8671233.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2636-43 [9215835.001]
  • [Cites] Gen Diagn Pathol. 1997 Nov;143(2-3):159-71 [9443572.001]
  • [Cites] J Reprod Med. 1998 Jan;43(1):81-6 [9475154.001]
  • [Cites] Br J Obstet Gynaecol. 1998 Sep;105(9):1032-5 [9763059.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):343-4 [10366456.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):345-7 [10366457.001]
  • [Cites] Obstet Gynecol. 1999 Oct;94(4):588-90 [10511364.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Jan 14;288(6411):103-6 [6318876.001]
  • [Cites] Cancer. 1985 May 15;55(10):2348-52 [2985232.001]
  • [Cites] Br J Obstet Gynaecol. 1986 Jan;93(1):63-9 [3002420.001]
  • [Cites] Am J Clin Oncol. 2000 Jun;23(3):244-8 [10857886.001]
  • (PMID = 11857007.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Other-IDs] NLM/ PMC2746538
  •  go-up   go-down


Advertisement
4. Xue WC, Chan KY, Feng HC, Chiu PM, Ngan HY, Tsao SW, Cheung AN: Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma. J Mol Diagn; 2004 Nov;6(4):326-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma.
  • The methylation status of genes in hydatidiform mole and choriocarcinoma and its significance is relatively unexplored.
  • We investigated the methylation status of the promoter regions of six genes, p16, HIC-1, TIMP3, GSTP1, death-associated protein kinase (DAPK), and E-cadherin in 54 hydatidiform moles, five choriocarcinomas, and 10 first trimester placenta by methylation-specific polymerase chain reaction (PCR).
  • Immunohistochemical expression of p16, TIMP3, and E-cadherin, and quantitative real-time RT-PCR of p16 was also performed.
  • Among the six genes examined, the promoter region of four genes (E-cadherin, HIC-1, p16, TIMP3) in choriocarcinoma and three genes (E-cadherin, HIC-1, p16) in hydatidiform mole exhibited aberrant methylation whereas none was hypermethylated in normal placenta.
  • Fifteen of the 54 patients with hydatidiform mole developed gestational trophoblastic neoplasia requiring chemotherapy.
  • [MeSH-major] Choriocarcinoma / genetics. DNA Methylation. Hydatidiform Mole / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Apoptosis Regulatory Proteins. Cadherins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Primers / chemistry. DNA-Binding Proteins. Death-Associated Protein Kinases. Female. Glutathione S-Transferase pi. Glutathione Transferase / genetics. Humans. Immunohistochemistry. Isoenzymes / genetics. Kruppel-Like Transcription Factors. Placenta / metabolism. Polymerase Chain Reaction. Pregnancy. Reverse Transcriptase Polymerase Chain Reaction / methods. Tissue Inhibitor of Metalloproteinase-3 / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2704-13 [10537333.001]
  • [Cites] Mod Pathol. 1999 Nov;12(11):1025-33 [10574599.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):588-92 [10645228.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):129-33 [10646864.001]
  • [Cites] Hunan Yi Ke Da Xue Xue Bao. 1998;23(1):17-20 [10681785.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):632-5 [10797283.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):673-9 [10931468.001]
  • [Cites] Am J Obstet Gynecol. 2000 Dec;183(6):1579-82 [11120531.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • [Cites] Biotechniques. 2001 Jan;30(1):66-72 [11196322.001]
  • [Cites] Histopathology. 2001 Mar;38(3):243-9 [11260306.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1982-6 [11448914.001]
  • [Cites] Placenta. 2002 Jan;23(1):20-31 [11869089.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1207-14 [11943705.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13787-95 [11827969.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1573-81 [12000709.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):438-44 [12051871.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1073-8 [7747802.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Carcinogenesis. 1996 Sep;17(9):1805-11 [8824499.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):39-47 [9062579.001]
  • [Cites] Dev Genet. 1997;21(1):61-7 [9291581.001]
  • [Cites] Oncogene. 1998 Apr 23;16(16):2159-64 [9572497.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2310-5 [9622064.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16778-81 [9642234.001]
  • [Cites] Oncogene. 1998 Jul 30;17(4):419-24 [9696034.001]
  • [Cites] Leukemia. 1999 Jun;13(6):877-83 [10360376.001]
  • [Cites] Gynecol Oncol. 1999 Nov;75(2):248-53 [10525381.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3794-7 [12097291.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4151-6 [12124354.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4545-8 [12183402.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1015-22 [12213730.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3164-71 [12374684.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):5336-9 [12414911.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):63-70 [12496700.001]
  • [Cites] Nat Med. 2003 Apr;9(4):407-15 [12652295.001]
  • [Cites] Lab Invest. 2003 May;83(5):697-709 [12746479.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):382-7 [12845678.001]
  • [Cites] Biol Chem. 2003 Jul;384(7):1029-34 [12956419.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2003 Dec;17(6):849-68 [14614885.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):879-88 [14675328.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):40-8 [14631372.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):704-7 [8259215.001]
  • (PMID = 15507671.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Isoenzymes; 0 / Kruppel-Like Transcription Factors; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / Transcription Factors; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  • [Other-IDs] NLM/ PMC1867494
  •  go-up   go-down


5. Wei CH, Shoo BA, Zedek DC, Kashani-Sabet M, Sagebiel RW, Leong SP: Rapidly lethal metastatic melanoma arising from a large congenital melanocytic naevus. BMJ Case Rep; 2009;2009
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly lethal metastatic melanoma arising from a large congenital melanocytic naevus.
  • A case of fatal metastatic melanoma arising from a very large congenital melanocytic naevus (VLCMN) is reported.
  • A 19-year-old man with a large congenital melanocytic naevus (LCMN) presented with a new nodule on the left chest wall, which was diagnosed as a thick melanoma with synchronous axillary lymph-node metastasis.
  • The patient developed widespread distant metastasis within weeks after surgical resection of the primary site and lymph-node basin, which was unresponsive to systemic chemotherapy and whole brain radiation therapy, and he died 7 months after diagnosis of the primary melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):789-92 [15097968.001]
  • [Cites] Br J Plast Surg. 2004 Dec;57(8):707-19 [15544766.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):512-7 [15787820.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):793-7 [15858468.001]
  • [Cites] Br J Dermatol. 2006 Jul;155(1):1-8 [16792745.001]
  • [Cites] J Invest Dermatol. 2007 Jan;127(1):179-82 [16888631.001]
  • [Cites] Hum Pathol. 1973 Sep;4(3):395-418 [4756859.001]
  • [Cites] Plast Reconstr Surg. 1981 Jun;67(6):782-90 [7243980.001]
  • [Cites] Am J Dermatopathol. 2006 Aug;28(4):377-9 [16871049.001]
  • [Cites] Arch Dermatol Res. 1991;283(7):438-44 [1801653.001]
  • [Cites] Br J Dermatol. 1981 Mar;104(3):307-15 [7213564.001]
  • (PMID = 21686526.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027522
  •  go-up   go-down


6. Todea V, Stan C, David C, Kauksar E, Călugăru M: [Trigeminal neuropathy, diagnostic and treatment problems]. Oftalmologia; 2002;55(4):34-8
MedlinePlus Health Information. consumer health - Glaucoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trigeminal neuropathy, diagnostic and treatment problems].
  • AIM OF THE STUDY: Clinical evaluation of patients with the diagnosis of Sturge-Weber syndrome (encephalotrigeminal angiomathosis) for establishing an accurate diagnosis and therapy.
  • RESULTS: The analysis of our cases showed that glaucoma does not correlate with the extension of skin lesion (nevus flammeus).
  • The outcome of glaucoma's therapy is dictated by the adjustment of the therapy to the type of glaucoma.
  • CONCLUSION: Glaucoma associated with the Sturge-Weber syndrome has always proved to be a therapeutic challenge and remains one of the causes of increased intraocular pressure, difficult to control.
  • The management of glaucoma in Sturge-Weber syndrome includes surgical and drug therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12723175.001).
  • [ISSN] 1220-0875
  • [Journal-full-title] Oftalmologia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Oftalmologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


7. Matsui H, Iitsuka Y, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K, Sekiya S: Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole. Tumour Biol; 2003 May-Jun;24(3):140-6
Genetic Alliance. consumer health - Hydatidiform mole.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole.
  • OBJECTIVES: To evaluate the spontaneous regression curve of serum human chorionic gonadotropin (hCG) in patients with an uneventful course after evacuation of hydatidiform mole and to compare the criteria for initiating chemotherapy in patients after evacuation of mole.
  • METHODS: From 1986 to 2001, 608 patients were followed at our department after evacuation of mole.
  • RESULTS: After evacuation of mole, the titers of serum hCG decreased constantly, and 90% of patients with an uneventful course were within normal range within 16 weeks.
  • Moreover, 39 (9.0%) and 15 patients (3.5%) with an uneventful course might have been diagnosed with gestational trophoblastic tumor and received needless chemotherapy based on the normal regression curve established by the Japan Society of Obstetrics and Gynecology or the US criteria of 4 consecutive plateauing or rising hCG values, respectively.
  • CONCLUSIONS: Our more selective criteria for initiating chemotherapy in patients after evacuation of mole, i.e. hCG of 10,000 mIU/ml at 5 weeks, 1,000 mIU/ml at 8 weeks and nondetectable levels at 24 weeks after evacuation of mole, may be safe and acceptable in the management of patients after evacuation of mole.
  • [MeSH-major] Chorionic Gonadotropin / blood. Gestational Trophoblastic Disease / drug therapy. Gestational Trophoblastic Disease / surgery. Hydatidiform Mole / drug therapy. Hydatidiform Mole / surgery
  • [MeSH-minor] Female. Humans. Immunoenzyme Techniques. Pregnancy. Radioimmunoassay. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14610317.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


8. Aida K, Monia K, Ahlem S, Dominique HT, Becima F, Sylvie F, Ridha KM: Agminated Spitz nevi arising on a nevus spilus after chemotherapy. Pediatr Dermatol; 2010 Jul-Aug;27(4):411-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agminated Spitz nevi arising on a nevus spilus after chemotherapy.
  • Agminated Spitz nevus arising on a background of nevus spilus (NS) is a rare condition.
  • We report here a further case in a child that is original because it is induced by chemotherapy.
  • A 3-year-old boy presented 3 months after the onset of a chemotherapy for a vesico-prostatic rhabdomyosarcoma, multiple pigmented papulo-nodules located on the face, neck, chest wall, and the higher back.
  • These lesions have arose on a pre-existent large congenital histologically confirmed nevus spilus extending along the face, neck, the left shoulder and the left chest wall.
  • Histological examination of three excised nodules led to the diagnosis of Spitz nevus.
  • Our patient may have a high risk for melanoma since he has many criteria predisposing to this risk.
  • Some of these criteria are related to NS but we should also take into account the chemotherapy induction and the high number of Spitz nevi.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Nevus, Epithelioid and Spindle Cell / chemically induced. Prostatic Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy. Skin Neoplasms / chemically induced. Urinary Bladder Neoplasms / drug therapy


9. Deng L, Yan X, Zhang J, Wu T: Combination chemotherapy for high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev; 2009;(2):CD005196
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy for high-risk gestational trophoblastic tumour.
  • BACKGROUND: Gestational trophoblastic disease (GTD) includes gestational trophoblastic tumour and hydatidiform mole.
  • A number of chemotherapy regimens are used for treating the disease, such as methotrexate, actinomycin D and cyclophosphamide (MAC), methotrexate, actinomycin D, cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine (CHAMOC), etoposide, methotrexate and actinomycin (EMA) plus cyclophosphamide and vincristine (CO) (EMA-CO), etoposide, methotrexate and actinomycin (EMA) plus etoposide and cisplatin(EP) (EMA-EP).
  • The efficacy of these drugs has not been systematically reviewed.
  • OBJECTIVES: To determine the efficacy and safety of combination chemotherapy in treating high-risk GTT.
  • SELECTION CRITERIA: The review included randomised controlled trials (RCTs) or quasi-RCTs of combination chemotherapy for treating high-risk GTT.
  • Patients with placental-site trophoblastic tumour (PSTT), who had received chemotherapy in the previous two weeks, or patients with chemotherapy intolerance were excluded.
  • AUTHORS' CONCLUSIONS: The methodological limitations of the included study prevent any firm conclusions about the best combination chemotherapy regimen for high-risk GTT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gestational Trophoblastic Disease / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Hydatidiform Mole / drug therapy. Hydroxyurea / administration & dosage. Melphalan / administration & dosage. Methotrexate / administration & dosage. Pregnancy. Trophoblastic Tumor, Placental Site / drug therapy. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;1:CD005196 [23440800.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2006;(3):CD005196 [16856085.001]
  • (PMID = 19370618.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; X6Q56QN5QC / Hydroxyurea; YL5FZ2Y5U1 / Methotrexate; MAC combination
  • [Number-of-references] 42
  •  go-up   go-down


10. Xue Y, Zhang J, Wu TX, An RF: Combination chemotherapy for high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev; 2006;(3):CD005196
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy for high-risk gestational trophoblastic tumour.
  • BACKGROUND: Gestational trophoblastic disease (GTD) includes gestational trophoblastic tumour and hydatidiform mole.
  • A number of chemotherapy regimens are used for treating the disease, such as methotrexate, actinomycin D and cyclophosphamide (MAC), methotrexate, actinomycin D, cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine (CHAMOC), etoposide, methotrexate and actinomycin (EMA) plus cyclophosphamide and vincristine (CO) (EMA-CO), etoposide, methotrexate and actinomycin (EMA) plus etoposide and cisplatin(EP) (EMA-EP).
  • The efficacy of these drugs has not been systematically reviewed.
  • OBJECTIVES: To determine the efficacy and safety of combination chemotherapy in treating high-risk GTT.
  • SELECTION CRITERIA: The review included randomized controlled trials (RCTs) or quasi-RCTs of combination chemotherapy for treating high-risk GTT.
  • Patients with placental-site trophoblastic tumour (PSTT), who had received chemotherapy in the previous two weeks, or patients with chemotherapy intolerance were excluded.
  • AUTHORS' CONCLUSIONS: The methodological limitations of the included study prevent any firm conclusions about the best combination chemotherapy regimen for high-risk GTT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gestational Trophoblastic Disease / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Hydatidiform Mole / drug therapy. Hydroxyurea / administration & dosage. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Pregnancy. Trophoblastic Tumor, Placental Site / drug therapy. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2009;(2):CD005196 [19370618.001]
  • (PMID = 16856085.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; X6Q56QN5QC / Hydroxyurea; YL5FZ2Y5U1 / Methotrexate; CHAMOMA protocol
  • [Number-of-references] 40
  •  go-up   go-down


11. Kendall A, Gillmore R, Newlands E: Chemotherapy for trophoblastic disease: current standards. Curr Opin Obstet Gynecol; 2002 Feb;14(1):33-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for trophoblastic disease: current standards.
  • Gestational trophoblastic diseases comprise a rare spectrum of disorders in which the normal regulatory mechanisms controlling the behaviour of trophoblastic tissue are lost.
  • They vary from the benign complete and partial hydatidiform moles to the frankly malignant choriocarcinoma and placental site trophoblastic tumours.
  • The majority will be cured by suction curettage, followed by human chorionic gonadotrophin screening, but some will go on to need chemotherapy.
  • Patients should have their treatment stratified according to various prognostic factors in order to ensure firstly their disease is eliminated and secondly to reduce the incidence of long-term treatment complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Neoplasm Staging. Pregnancy. Prognosis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801874.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 13
  •  go-up   go-down


12. Matsui H, Iitsuka Y, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Sekiya S: Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor. J Reprod Med; 2004 Jul;49(7):531-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor.
  • OBJECTIVE: To analyze the outcome of the first pregnancy following chemotherapy for gestational trophoblastic tumor (GTT).
  • STUDY DESIGN: A total of 393 patients with GTT (87 with high-risk and 306 with low-risk GTT) underwent chemotherapy at Chiba University Hospital between 1974 and 2000.
  • Of them, 137 (19 with high-risk and 118 with low-risk GTT) who achieved primary remission and had at least 1 conception following chemotherapy were included in the study.
  • RESULTS: The overall outcomes of the first subsequent pregnancies in the 137 women treated with chemotherapy were comparable to those in the general Japanese population.
  • However, the incidence of abnormal pregnancies (spontaneous abortion, stillbirth, repeat mole) was significantly higher in women who conceived within 6 months of completing chemotherapy (6 of 16, 37.5%) than in those who conceived after the recommended waiting period, > 12 months (11 of 99, 10.5%) (P=.014).
  • CONCLUSION: Patients who achieved primary remission with various kinds of chemotherapy may anticipate a normal future reproductive outcome.
  • As pregnancies occurring within 6 months following remission are at risk of abnormality, a waiting period of at least 6 months after chemotherapy for GTT is recommended.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gestational Trophoblastic Disease / drug therapy. Pregnancy Complications / chemically induced. Pregnancy Outcome. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Pregnancy. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15305824.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Matsui H, Iitsuka Y, Suzuka K, Yamazawa K, Tanaka N, Seki K, Sekiya S: Risk of abnormal pregnancy completing chemotherapy for gestational trophoblastic tumor. Gynecol Oncol; 2003 Feb;88(2):104-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of abnormal pregnancy completing chemotherapy for gestational trophoblastic tumor.
  • OBJECTIVE: This study analyzed the outcome of the first pregnancy following chemotherapy for gestational trophoblastic tumor (GTT).
  • METHODS: A total of 387 patients with GTT (85 patients with high-risk GTT and 302 patients with low-risk GTT) underwent chemotherapy at Chiba University Hospital between 1974 and 2000.
  • Of these patients, 130 women (18 with high-risk GTT and 112 with low-risk GTT), who achieved remission and had at least one conception following chemotherapy, were included in the study.
  • RESULTS: The outcomes of all the first subsequent pregnancies in women treated with methotrexate, actinomycin-D, or etoposide (including those switched to other regimens), or combination therapy, were comparable to those in the Japanese general population.
  • However, the incidence of abnormal pregnancies (spontaneous abortion, still birth, repeat mole) was significantly higher in women who conceived within 6 months of completing chemotherapy (4/15; 40%) than in those who conceived after the recommended waiting period of more than 12 months (10/95; 10.5%) (P = 0.028).
  • CONCLUSION: Patients with GTT who achieved remission after chemotherapy with methotrexate, actinomycin-D, or etoposide, or combination therapy, may anticipate a normal future reproductive outcome.
  • As pregnancies occurring within 6 months following remission are at risk of abnormalities, a waiting period of at least 6 months after chemotherapy for GTT is suggested.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gestational Trophoblastic Disease / drug therapy. Gestational Trophoblastic Disease / physiopathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dactinomycin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Methotrexate / therapeutic use. Pregnancy. Pregnancy Outcome. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12586587.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Pariyar J: Gestational trophoblastic disease in Nepalese women managed in B. P. Koirala Memorial Cancer Hospital. J Clin Oncol; 2009 May 20;27(15_suppl):e16570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main outcomes were measured in terms of duration, antecedent pregnancy, investigations, treatment and follow-up.
  • There were 17 cases (37.8%) of hydatidiform mole, 6 were invasive mole (13.35%), 4 of persistent gestational trophoblastic tumour (8.8%) and 22 patients (48.8%) of choriocarcinoma.
  • Among the 45 cases 6 (13.3%) were treated with suction evacuation only; 9 (20%) underwent hysterectomy for uterine perforation, excessive hemorrhage and invasive mole.
  • 28 (62.2%) cases underwent adjuvant chemotherapy among which 12 (26.6%) received single agent chemotherapy and 15 (33.3%) received EMA-CO regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kendall A, Gillmore R, Newlands E: Chemotherapy for trophoblastic disease: current standards. Expert Rev Anticancer Ther; 2003 Feb;3(1):48-54
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for trophoblastic disease: current standards.
  • Gestational trophoblastic diseases comprise a rare spectrum of disorders in which the normal regulatory mechanisms controlling the behavior of trophoblastic tissue are lost.
  • They vary from the benign complete and partial hydatidiform moles to the frankly malignant choriocarcinoma and placental site trophoblastic tumors.
  • The majority will be cured by suction curettage, followed by human chorionic gonadotrphin screening but some will go on to need chemotherapy.
  • Patients should have their treatment stratified according to various prognostic factors in order to ensure firstly their disease is eliminated and secondly to reduce the incidence of long-term treatment complications.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Drug Resistance, Neoplasm. Female. Humans. Neoplasm Staging. Placenta / pathology. Pregnancy. Prognosis. Risk Assessment

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12597349.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 14
  •  go-up   go-down


16. Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS: Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. J Reprod Med; 2010 Jul-Aug;55(7-8):279-84
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
  • OBJECTIVE: To determine whether any clinical parameters predict the need for multiagent chemotherapy for treatment of low-risk gestational trophoblastic neoplasia (GTN) after the development of methotrexate (MTX) resistance.
  • RESULTS: We analyzed data from 150 women (40 with partial mole, 110 with complete mole) who received single-agent MTX for low-risk GTN using FIGO and WHO scoring systems.
  • Of the 45 women who developed MTX resistance, the majority (37/45) of these patients received actinomycin D, with 10 patients ultimately requiring multiagent chemotherapy.
  • The requirement for multiagent chemotherapy following MTX resistance was associated with a beta-hCG > 600 mlU/mL 1 week following initial MTX therapy (p < 0.03).
  • Conversely, a beta-hCG < 600 mlU/mL 1 week following initial MTX therapy was as-sociated with a 93% probability of remission with actinomycin D alone.
  • CONCLUSION: The prognosis for patients with low-risk GTN following molar gestation is excellent, with 100% remission rate, though a small but significant proportion (7%) required multiagent chemotherapy.
  • The need for multiagent chemotherapy was associated with beta-hCG levels 1 week following initial MTX therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Gestational Trophoblastic Disease / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Cyclophosphamide / therapeutic use. Dactinomycin / administration & dosage. Dactinomycin / therapeutic use. Etoposide / administration & dosage. Female. Humans. Middle Aged. Pregnancy. Registries. Remission Induction. Retrospective Studies. Uterine Neoplasms / drug therapy. Uterine Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20795339.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Chorionic Gonadotropin, beta Subunit, Human; 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; MAC combination
  •  go-up   go-down


17. Ino K, Mitsui T, Nomura S, Kikkawa F, Mizutani S: Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature. Gynecol Oncol; 2001 Dec;83(3):601-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature.
  • She had undergone evacuation of a complete hydatidiform mole 32 months prior to the presentation.
  • The patient received 13 courses of combination chemotherapy, resulting in complete remission.
  • Radiotherapy and surgical treatment were unnecessary.
  • CONCLUSION: This is a very rare case of the successful treatment of gestational choriocarcinoma metastatic to the choroid using systemic chemotherapy alone.
  • [MeSH-major] Choriocarcinoma / drug therapy. Choriocarcinoma / secondary. Choroid Neoplasms / drug therapy. Choroid Neoplasms / secondary. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2001 Elsevier Science.
  • (PMID = 11733980.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


18. Hossain N, Muzzafar N, Soomro N: Partial hydatidiform mole. J Coll Physicians Surg Pak; 2005 Jan;15(1):50-1
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial hydatidiform mole.
  • A case of partial hydatidiform mole is presented, occurring in a young primiparous woman after natural conception.
  • Histological diagnosis of partial mole was made.
  • Failure of beta HCG to fall resulted in the start of chemotherapy.
  • In spite of the low risk, she required third line chemotherapy for complete eradication of disease.
  • [MeSH-major] Hydatidiform Mole, Invasive / drug therapy. Hydatidiform Mole, Invasive / pathology. Uterine Neoplasms / drug therapy. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670529.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


19. Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW: Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol; 2000 Sep;78(3 Pt 1):309-12
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy.
  • OBJECTIVES: The aim of this study was to assess whether there was a change in the mode of evacuation of GTD over two time periods and to assess whether mode of evacuation influenced the subsequent need for chemotherapy.
  • METHODS: A retrospective case note study of 4257 cases between 1986 and 1996, at a screening and treatment center managing GTD, was performed.
  • RESULTS: Between the time periods 1986-1989 and 1990-1996 there was significant change in the mode of evacuation to suction curettage.
  • The mode of evacuation was significant in determining the need for chemotherapy.
  • The highest rate of chemotherapy was associated with medical methods of evacuation.
  • CONCLUSIONS: Suction curettage is a safe method of uterine evacuation in GTD and its usage has increased with time.
  • Medical methods of uterine evacuation are associated with higher rates of chemotherapy.
  • Medical methods of evacuation should not be used in cases of complete hydatiform mole.
  • [MeSH-major] Dilatation and Curettage / methods. Hydatidiform Mole / drug therapy. Hydatidiform Mole / surgery. Uterine Neoplasms / drug therapy. Uterine Neoplasms / surgery
  • [MeSH-minor] Abortifacient Agents, Steroidal / adverse effects. Abortifacient Agents, Steroidal / therapeutic use. Female. Humans. Mifepristone / adverse effects. Mifepristone / therapeutic use. Oxytocin / adverse effects. Oxytocin / therapeutic use. Pregnancy. Prostaglandins / adverse effects. Prostaglandins / therapeutic use. Retrospective Studies. Vacuum Curettage / adverse effects. Vacuum Curettage / methods. Vacuum Curettage / trends

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. Oxytocin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10985885.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Abortifacient Agents, Steroidal; 0 / Prostaglandins; 320T6RNW1F / Mifepristone; 50-56-6 / Oxytocin
  •  go-up   go-down


20. Uberti EM, Fajardo Mdo C, Ferreira SV, Pereira MV, Seger RC, Moreira MA, Torres MD, de Nápoli G, Schmid H: Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecol Oncol; 2009 Dec;115(3):476-81
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy.
  • OBJECTIVE: To evaluate whether prophylactic chemotherapy (P-chem) with one bolus dose of actinomycin D (Act-D) during the uterine evacuation of patients with high-risk hydatidiform mole (Hr-HM) affects reproductive outcomes in subsequent pregnancies.
  • From 1996 to 2006, 163 received one bolus dose of Act-D at the time of uterine evacuation (Hr-HM-chem group); 102 with the same risk factors did not get P-chem (Hr-HM-control group).
  • Type of subsequent pregnancy was not statistically different between groups, and the rate of live births associated with pregnancies for which US showed a live fetus was high.
  • [MeSH-major] Dactinomycin / administration & dosage. Hydatidiform Mole / drug therapy. Hydatidiform Mole / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Pregnancy. Pregnancy Outcome. Reproduction. Young Adult

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19818481.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


21. Durrieu G, Rigal M, Bugat R, Lapeyre-Mestre M: Fertility and outcomes of pregnancy after chemotherapy in a sample of childbearing aged women. Fundam Clin Pharmacol; 2004 Oct;18(5):573-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility and outcomes of pregnancy after chemotherapy in a sample of childbearing aged women.
  • The aim of the study was to review the characteristics and outcomes of pregnancies occurring in women of childbearing age after chemotherapy for malignant disease.
  • Between November 1998 and October 1999, a total of 16 patients who were treated for ovary (three), mole (one), vaginal (one), breast (four), Hodgkin's disease (four), lung (one), melanoma (one) and osteosarcoma (one) carcinoma were identified and retrospectively questioned about their fertility status.
  • Five patients (31%) experienced anomalies of hormonal cycle during and after the treatment.
  • The 16 women had 21 pregnancies resulting in 18 normal infants, one newborn with a minor abnormality (tallus foot), one spontaneous abortion and one lost of follow-up to 6 months of pregnancy.
  • The present survey suggests that cytotoxic drug exposure had no deleterious effects on subsequent pregnancies.
  • A prospective and systemic survey would be the only means able to clarify the actual cancer therapy on reproductive outcome and to investigate the long-term effects in the progeny.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Fertility / drug effects. Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Abnormalities, Drug-Induced / epidemiology. Abnormalities, Drug-Induced / etiology. Abortion, Spontaneous / epidemiology. Abortion, Spontaneous / etiology. Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Infant, Newborn. Pregnancy. Pregnancy Outcome / epidemiology. Premature Birth / epidemiology. Premature Birth / etiology. Retrospective Studies. Time Factors. Treatment Outcome


22. Sáez Rodríguez M, Rodríguez-Martin M, Carnerero A, Sidro M, Rodríguez F, Cabrera R, Guimerá F, García M, Sánchez R, Noda A: Naevus lipomatosus cutaneous superficialis on the nose. J Eur Acad Dermatol Venereol; 2005 Nov;19(6):751-2
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Naevus lipomatosus cutaneous superficialis on the nose.
  • Naevus lipomatosus cutaneous superficialis (NLCS) is an uncommon hamartomatous lesion with an exceptional presentation on the face.
  • We report the case of an elderly patient who presented with a classic type of NLCS on the right nasal orifice.
  • [MeSH-major] Lipomatosis / diagnosis. Nevus / diagnosis. Nose Neoplasms / diagnosis
  • [MeSH-minor] Administration, Inhalation. Aged. Diagnosis, Differential. Humans. Male. Rhinitis, Allergic, Perennial / drug therapy. Steroids / administration & dosage

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16268886.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Steroids
  •  go-up   go-down


23. Zavadil M, Toman J, Kucera E, Feyereisl J, Safár P, Pán M: [Proliferating mole in menopause imitating choriocarcinoma recurrence--case report]. Ceska Gynekol; 2002 Sep;67(5):278-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Proliferating mole in menopause imitating choriocarcinoma recurrence--case report].
  • OBJECTIVE: To show the possibility of new invasive mole arising after 2 years of menopause, after choriocarcinoma cured by chemotherapy 5 years ago.
  • CASE REPORT: Patient 50-years-old with choriocarcinoma, in consequence to invasive mole, was cured by chemotheraphy.
  • After 5 years of clinical and laboratory remission and after two years of menopause new pregnancy with invasive mole arised imitating relapse of choriocarcinoma.

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12434664.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


24. Lan Z, Hongzhao S, Xiuyu Y, Yang X: Pregnancy outcomes of patients who conceived within 1 year after chemotherapy for gestational trophoblastic tumor: a clinical report of 22 patients. Gynecol Oncol; 2001 Oct;83(1):146-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for gestational trophoblastic tumor .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy outcomes of patients who conceived within 1 year after chemotherapy for gestational trophoblastic tumor: a clinical report of 22 patients.
  • OBJECTIVE: The aim of this study was to explore the risk of pregnancy of patients who conceived within 1 year after successful chemotherapy for gestational trophoblastic tumor (GTT).
  • METHODS: From 1966 to 1996, 22 patients who conceived within 1 year after chemotherapy were followed up and analyzed retrospectively.
  • RESULTS: Among 22 patients, 9 had term deliveries and 1 had a premature birth, 6 had induced abortion at the patient's request, and 6 had therapeutic abortion because of various indications such as repeated hydatidiform mole (1 case), intrauterine death (1 case), inevitable abortion (1 case), and threatened abortion (3 cases).
  • The average interval between completion of chemotherapy and pregnancy was 10.25 months in the group of term pregnancies and 5.86 months in that of fetal loss (P < 0.05), indicating that the longer the interval, the lesser the risk of GTD.
  • CONCLUSION: The results suggest that contraception for 1 year is necessary in patients with GTT after successful chemotherapy.
  • [MeSH-major] Choriocarcinoma / drug therapy. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Staging. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11585428.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 5
  •  go-up   go-down


25. Seckl MJ, Fisher RA, Salerno G, Rees H, Paradinas FJ, Foskett M, Newlands ES: Choriocarcinoma and partial hydatidiform moles. Lancet; 2000 Jul 1;356(9223):36-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choriocarcinoma and partial hydatidiform moles.
  • BACKGROUND: Partial hydatidiform moles (PMs) rarely require chemotherapy and have never previously been proven to transform into choriocarcinoma, the most malignant form of gestational trophoblastic disease (GTD).
  • METHODS: Patients with a PM who developed a subsequent choriocarcinoma were identified from our GTD database.
  • FINDINGS: Of the 3000 patients with PM, 15 required chemotherapy for persisting GTD.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Choriocarcinoma / diagnosis. Hydatidiform Mole / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Alleles. Chorionic Gonadotropin / blood. Female. Flow Cytometry. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Microsatellite Repeats. Polyploidy. Pregnancy

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2000 Oct 21;356(9239):1443-4 [11052615.001]
  • (PMID = 10892763.001).
  • [ISSN] 0140-6736
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


26. Kim SJ, Na YJ, Jung SG, Kim CJ, Bae SN, Lee C: Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience. J Reprod Med; 2007 Sep;52(9):819-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience.
  • OBJECTIVE: To test the efficacy of a new scoring system to differentiate high-risk hydatidiform mole (H-mole) and initiate early selective postmolar chemotherapy.
  • STUDY DESIGN: According to Kim's scoring system, 262 patients were identified as high-risk H-mole patients.
  • Fifty (19.1%) received early chemotherapy, and the rest constituted the control group.
  • Salvage therapy with etoposide, methotrexate, actinomycin D/etoposide, cisplatin (EMA/EP) and taxol, cisplatin/taxol, etoposide (TP/TE) was applied in 21 cases of ultra-high-risk GTT.
  • RESULTS: None of the 50 cases in the early chemotherapy group progressed to persistent GTT.
  • However, 58.9% in the control group developed GTT with 8.0% drug resistance.
  • Of those receiving salvage therapy in the 21 ultra-high-risk GTT cases resistant to EMA/CO, 10 of 14 (71%) receiving EMA/EP and 4 of 7 (57.1%) receiving TP/TE achieved remission.
  • CONCLUSION: Early postmolar chemotherapy for high-risk H-mole is effective in preventing progression to persistent GTT and treatment failure.
  • Ultra-high-risk GTT should be approached with multimodal treatment, including EMA/EP and TP/TE regimens.
  • [MeSH-major] Hydatidiform Mole / drug therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cisplatin / administration & dosage. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Korea. Methotrexate / administration & dosage. Middle Aged. Paclitaxel / administration & dosage. Pregnancy. Prospective Studies. Registries. Retrospective Studies. Risk Factors. Salvage Therapy. Severity of Illness Index

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939600.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Seckl MJ, Dhillon T, Dancey G, Foskett M, Paradinas FJ, Rees HC, Sebire N, Vigushin DM, Newlands ES: Increased gestational age at evacuation of a complete hydatidiform mole: does it correlate with increased risk of requiring chemotherapy? J Reprod Med; 2004 Jul;49(7):527-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased gestational age at evacuation of a complete hydatidiform mole: does it correlate with increased risk of requiring chemotherapy?
  • OBJECTIVE: To assess whether a complete hydatidiform mole (CHM) carries an increased risk of later requiring chemotherapy in pregnancies continued to term.
  • STUDY DESIGN: The Charing Cross gestational trophoblastic neoplasia (GTN) database was screened between 1973 and 2002 to identify registered singleton CHMs with a known gestational age at the time of evacuation.
  • RESULTS: For the total population, including non-centrally reviewed patients, evacuation occurring in the first, second or third trimester was associated with a treatment rate of 13.9% (601 of 4,333), 10.8% (412 of 3,803) and 5.1% (9 of 177), respectively.
  • In patientsfor whom a central pathologic review had been performed to confirm the diagnosis, the treatment rates were 27.7% (525 of 1,897), 27% (241 of 893) and 20% (2 of 10).
  • The higher apparent treatment rates reflect an error in the denominator as we do not review all nontreated cases.
  • In the total population, evacuation in the third trimester correlated with a reduction in risk of subsequent treatment (P<.001).
  • CONCLUSION: There is no evidence that delayed evacuation/delivery of singleton CHM increases the risk of subsequently requiring chemotherapy.
  • [MeSH-major] Cell Transformation, Neoplastic. Hydatidiform Mole / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Gestational Age. Humans. Obstetric Surgical Procedures / methods. Pregnancy. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15305823.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Ilyas EN, Goldsmith K, Lintner R, Manders SM: Rhabdomyosarcoma arising in a giant congenital melanocytic nevus. Cutis; 2004 Jan;73(1):39-43
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma arising in a giant congenital melanocytic nevus.
  • We report the case of a 6-week-old girl who presented with a pedunculated embryonal rhabdomyosarcoma arising in a giant congenital melanocytic nevus (GCMN) on her lower back.
  • The patient underwent surgical resection of the rhabdomyosarcoma at age 2 months, with subsequent chemotherapy consisting of actinomycin D and vincristine.
  • [MeSH-major] Nevus, Pigmented / pathology. Precancerous Conditions / pathology. Rhabdomyosarcoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Infant. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14964630.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


29. Hussein MR, Abd-Elwahed AR, Abodeif ES, Abdulwahed SR: Decidual immune cell infiltrate in hydatidiform mole. Cancer Invest; 2009 Jan;27(1):60-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decidual immune cell infiltrate in hydatidiform mole.
  • BACKGROUND: Hydatidiform mole is a gestational trophoblastic disease characterized by proliferation of the pregnancy-associated trophoblastic tissue.
  • Complete hydatidiform mole is an entirely paternally derived lesion, and therefore, represents complete intrauterine allografts that can induce an altered maternal immune response Hypothesis: Here, we hypothesize that "the development of hydatidiform moles is associated with numeric alterations of the decidual immune cell infiltrate."
  • MATERIALS AND METHODS: A total of 30 specimens (decidual tissue), entailing normal first trimester pregnancy terminations and complete hydatidiform moles (15 cases, each), were evaluated for immune cell infiltrate using immunohistological methods and monoclonal antibodies (CD20, CD68, and CD3 for B cells, histiocytes/dendritic cells, and T cells, respectively).
  • RESULTS: Groups of immune cells were seen in the decidual tissue of first trimester normal pregnancy terminations and hydatidiform moles.
  • Compared to the decidual tissue of first trimester normal pregnancy terminations, the mean counts of the immune cells were statistically significantly higher (p< 0.05) in the decidual tissue of the hydatidiform moles (0.33 +/- 0.21 vs. 1.66 +/- 0.21 for CD20(+)B cells; 9.80 +/- 1.57 vs. 13.14 +/- 1.16 for CD68(+) cells; and 12.92 +/- 3.46 vs. 23.85 +/- 1.22 for CD3(+) cells for decidual tissue without and with molar changes, respectively).
  • CONCLUSIONS: Hydatidiform moles are associated with numeric alterations of immune cell infiltrate.
  • The numeric dominance of immune cells in the hydatidiform moles may reflect either non-specific or specific immunological processes.
  • [MeSH-major] B-Lymphocytes / immunology. Decidua / immunology. Hydatidiform Mole / immunology. T-Lymphocytes / immunology. Uterine Neoplasms / immunology

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160109.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


30. Stanescu D, Wattenberg S, Cohen SY: Photodynamic therapy for choroidal neovascularization secondary to choroidal nevus. Am J Ophthalmol; 2003 Sep;136(3):575-6
Genetic Alliance. consumer health - Nevus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for choroidal neovascularization secondary to choroidal nevus.
  • PURPOSE: To describe a patient treated with photodynamic therapy for subfoveal choroidal neovascularization secondary to choroidal nevus.
  • METHODS: A 61-year-old woman presented with subfoveal choroidal neovascularization secondary to choroidal nevus and best-corrected visual acuity of 20/50.
  • The choroidal neovascularization was treated with two verteporfin photodynamic therapy sessions, separated by 3 months.
  • CONCLUSION: Photodynamic therapy seems to be an effective treatment for subfoveal choroidal neovascularization secondary to choroidal nevus.
  • [MeSH-major] Choroid Neoplasms / complications. Choroidal Neovascularization / drug therapy. Nevus, Pigmented / complications. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12967828.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


31. Holmes G, Wines N, Ryman W: Giant congenital melanocytic naevus and symptomatic thoracic arachnoid cyst. Australas J Dermatol; 2001 May;42(2):124-8
MedlinePlus Health Information. consumer health - Spinal Cord Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant congenital melanocytic naevus and symptomatic thoracic arachnoid cyst.
  • This case highlights the need to consider that the management of patients with giant congenital melanocytic naevus is variable depending on the age of the patient, the location of lesions and the presence of complications such as neurocutaneous melanosis.
  • [MeSH-major] Arachnoid Cysts / complications. Arachnoid Cysts / diagnosis. Nevus, Pigmented / complications. Skin Neoplasms / complications. Spinal Cord Diseases / complications. Spinal Cord Diseases / diagnosis
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Severity of Illness Index. Thoracic Vertebrae

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11309037.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


32. Niemann I, Hansen ES, Sunde L: The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy. Gynecol Oncol; 2007 Feb;104(2):411-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy.
  • OBJECTIVE: Hydatidiform mole can be classified by histopathologic characteristics and by genetic constitutions and most complete moles are diploid, whereas most partial moles are triploid.
  • We investigated the concordance between these two classifications, characterized moles with conflicting classifications, and compared the ability of the two classifications to discriminate between patients with and without a substantial risk of persistent trophoblastic disease.
  • METHODS: 294 cases of consecutively collected hydropic placentas clinically suspected of hydatidiform mole made the basis of this retrospective study.
  • Data on possible chemotherapy were collected for each patient.
  • RESULTS: 270 of the conceptuses were histopathologically classified as hydatidiform mole.
  • 5% of the patients with hydropic placentas classified as partial mole encountered persistent trophoblastic disease; however, the genome was diploid in all these moles.
  • CONCLUSION: As full concordance between the histopathologic and the genetic classifications was not found, we believe that features beyond the genetic constitution influence the development of morphologic features in hydatidiform moles.
  • We recommend that gestations suspected of hydatidiform mole are subjected to histopathologic examination.
  • [MeSH-major] Hydatidiform Mole / genetics. Hydatidiform Mole / pathology. Ploidies. Trophoblastic Neoplasms / genetics. Trophoblastic Neoplasms / pathology. Uterine Neoplasms / genetics. Uterine Neoplasms / pathology
  • [MeSH-minor] Animals. Chickens. Choriocarcinoma / drug therapy. Choriocarcinoma / genetics. Choriocarcinoma / pathology. Female. Humans. Pregnancy. Retrospective Studies. Trout

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011616.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Fukushima S, Hatta N: Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug. Br J Dermatol; 2004 Sep;151(3):698-700
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug.
  • We present a patient with multiple pigmented lesions on the palms, soles, oral mucosa and nails after chemotherapy with oral 5-fluorouracil (5-FU) prodrug.
  • However, histologically, both types of lesion showed basal hyperpigmentation and the presence of a small number of large atypical melanocytes.
  • We diagnosed these lesions as pigment flecks induced by 5-FU, and the pigmented lesions gradually diminished after the cessation of chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Drug Eruptions / etiology. Fluorouracil / adverse effects. Hyperpigmentation / chemically induced. Prodrugs / adverse effects
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Melanoma / diagnosis. Skin Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15377362.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Han BG, Kim MH, Karl EH, Hong SW, Choi SO: A case of membranoproliferative glomerulonephritis associated with a hydatidiform mole. Yonsei Med J; 2000 Jun;41(3):407-10
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of membranoproliferative glomerulonephritis associated with a hydatidiform mole.
  • We treated a 54-year-old woman who was suffering from membranoproliferative glomerulonephritis associated with a complete type of hydatidiform mole.
  • Genralized edema, proteinuria and hematuria were completely recovered by suction and curettage of the hydatidiform mole with prophylactic chemotherapy.
  • The common feature of them was a complete remission of the nephropathy after the removal of the hydatidiform mole.
  • The relationship between the hydatidiform mole and glomerulonephritis remains unresolved at present.
  • But we concluded that the hydatidiform mole might be a cause of glomerulonephritis in this case.
  • [MeSH-major] Glomerulonephritis, Membranoproliferative / etiology. Hydatidiform Mole / complications. Hydatidiform Mole / diagnosis. Uterine Neoplasms / complications. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Glomerulonephritis.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10957899.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] KOREA (SOUTH)
  • [Number-of-references] 11
  •  go-up   go-down


35. Richter DU, Jeschke U, Makovitzky J, Gerber B, Briese V: Expression of the pantumour Thomsen-Friedenreich antigen in the human placenta with the diagnosis of hydatidiform mole. Anticancer Res; 2007 Jul-Aug;27(4A):2001-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the pantumour Thomsen-Friedenreich antigen in the human placenta with the diagnosis of hydatidiform mole.
  • MATERIALS AND METHODS: Paraffin-embedded placental and decidual tissues from patients with the diagnosis hydatidiform mole were incubated with different monoclonal antibodies directed against TF-epitope (CD 176, IgM) and against Mucin 1 (CD 227, IgG).
  • RESULTS: No expression of the TF-antigen or of Mucin 1 (Muc 1) was found in the decidual tissues, but the samples of chorionic tissues were TF- and Muc 1-antigen positive.
  • CONCLUSION: A disorder of the extravillous trophoblast cells is present in hydatidiform mole.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / biosynthesis. Hydatidiform Mole / diagnosis. Placenta / metabolism. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649812.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Mucin-1; 3554-90-3 / Thomsen-Friedenreich antigen
  •  go-up   go-down


36. Matsui H, Iitsuka Y, Suzuka K, Seki K, Sekiya S: Subsequent pregnancy outcome in patients with spontaneous resolution of HCG after evacuation of hydatidiform mole: comparison between complete and partial mole. Hum Reprod; 2001 Jun;16(6):1274-7
Genetic Alliance. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsequent pregnancy outcome in patients with spontaneous resolution of HCG after evacuation of hydatidiform mole: comparison between complete and partial mole.
  • This study compared subsequent pregnancy outcome in patients with complete and partial hydatidiform moles.
  • Among 1052 patients with molar pregnancy (complete mole, 801; partial mole, 251) monitored at Chiba University Hospital between 1981 and 1999, 891 patients (84.7%) had spontaneous resolution of human chorionic gonadotrophin (HCG) after mole evacuation, and 161 patients (15.3%) required chemotherapy.
  • The pregnancy outcome was not significantly different in patients with complete and partial moles, and was comparable with that in the general Japanese population.
  • The incidence of repeat molar pregnancy in patients with complete and partial mole (1.3 and 1.5% respectively) was 5-fold higher than that of the general population, while no increased risk of persistent gestational trophoblastic tumour (GTT) associated with later molar pregnancy was observed.
  • During HCG follow-up, 10 patients (1.1%) developed secondary high-risk GTT between 14 and 54 months after mole evacuation.
  • In conclusion, patients with complete and partial mole can anticipate a normal future reproductive outcome, and pregnancies after experiencing hydatidiform mole may not affect the development of high-risk GTT.
  • [MeSH-major] Chorionic Gonadotropin / blood. Hydatidiform Mole / surgery. Pregnancy Outcome

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11387305.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


37. McAllister JC, Petzold CR, Lio PA: Adverse effects of a mole removal cream. Pediatr Dermatol; 2009 Sep-Oct;26(5):628-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adverse effects of a mole removal cream.
  • Mole removal creams available over the Internet pose potential dangers to unsuspecting patients.
  • [MeSH-major] Keloid / chemically induced. Nevus / drug therapy. Nonprescription Drugs / adverse effects. Plant Preparations / adverse effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Over-the-Counter Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19840333.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nonprescription Drugs; 0 / Plant Preparations
  •  go-up   go-down


38. Niemann I, Sunde L, Petersen LK: Evaluation of the risk of persistent trophoblastic disease after twin pregnancy with diploid hydatidiform mole and coexisting normal fetus. Am J Obstet Gynecol; 2007 Jul;197(1):45.e1-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the risk of persistent trophoblastic disease after twin pregnancy with diploid hydatidiform mole and coexisting normal fetus.
  • OBJECTIVE: This study was undertaken to evaluate the risk of persistent trophoblastic disease and obstetric complications related to a multiple pregnancy comprising a diploid hydatidiform mole and normal cofetus(es).
  • STUDY DESIGN: From a database of 270 consecutively collected hydatidiform moles, 8 multiple and 154 singleton molar pregnancies were identified.
  • Molar and fetal ploidy was determined, and data on clinical features and chemotherapy were collected.
  • Five patients with diploid mole and coexisting fetus pregnancy chose to terminate their pregnancy, 2 aborted spontaneously, and 1 patient delivered a healthy child.
  • Two diploid mole and coexisting fetus pregnancies (25%) and 17% of the singleton molar pregnancies were followed by persistent trophoblastic disease (P = .63).
  • CONCLUSION: The risk of persistent trophoblastic disease after a diploid mole with coexisting fetus pregnancy is similar to that after a singleton molar pregnancy, and expectant management instead of therapeutic abortion can be pursued.
  • [MeSH-major] Hydatidiform Mole / complications. Pregnancy Complications, Neoplastic. Twins. Uterine Neoplasms / complications


39. Koc S, Ozdegirmenci O, Tulunay G, Ozgul N, Kose MF, Bulbul D: Recurrent partial hydatidiform mole: a report of a patient with three consecutive molar pregnancies. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):940-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent partial hydatidiform mole: a report of a patient with three consecutive molar pregnancies.
  • Hydatidiform mole (HM) is the most common form of gestational trophoblastic neoplasia and is characterized by atypical hyperplastic trophoblasts and hydropic villi.
  • A 28-year-old woman with gravida 3, para 0, was referred to our hospital with a diagnosis of an invasive mole in December 2003.
  • All three moles were histologically confirmed as partial moles.
  • In the first two molar events no additional treatment after evacuation was required, but in the last event, the beta-human chorionic gonadotropin levels increased and an invasive mole was suspected.
  • Diagnostic workup ruled out an invasive mole and choriocarcinoma.
  • The patient required chemotherapy for treatment of persistent disease.
  • Recurrent partial HM is a very rare clinical disorder.
  • Repetitive molar pregnancy is not an indication for chemotherapy, but persistent disease does require chemotherapy.
  • [MeSH-major] Hydatidiform Mole / diagnosis. Neoplasm Recurrence, Local / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Chorionic Gonadotropin, beta Subunit, Human / metabolism. Female. Humans. Hydatidiform Mole, Invasive / pathology. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681793.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


40. Horn LC, Kowalzik J, Bilek K, Richter CE, Einenkel J: Clinicopathologic characteristics and subsequent pregnancy outcome in 139 complete hydatidiform moles. Eur J Obstet Gynecol Reprod Biol; 2006 Sep-Oct;128(1-2):10-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and subsequent pregnancy outcome in 139 complete hydatidiform moles.
  • OBJECTIVE: The most common form of gestational trophoblastic disease is the complete hydatidiform mole (CHM).
  • Clinical characteristics, the need for chemotherapy and subsequent pregnancy outcome were evaluated.
  • RESULTS: Twelve out of 151 cases were re-evaluated as hydropic abortion, as partial hydatidiform moles or were insufficient for morphologic examination and therefore excluded from further analysis.
  • Twenty-six patients (19%) required chemotherapy because of gestational trophoblastic neoplasia (GTN; low-risk: 23 out of 26).
  • CONCLUSIONS: The clinical and morphologic diagnosis of CHM is a challenge, and diagnosis as well as treatment should be multidisciplinary and centralised.
  • [MeSH-major] Hydatidiform Mole / complications. Pregnancy Outcome. Uterine Neoplasms / complications

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16530318.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


41. Parodi MB, Boscia F, Piermarocchi S, Ferrari TM, Furino C, Sborgia C: Variable outcome of photodynamic therapy for choroidal neovascularization associated with choroidal nevus. Retina; 2005 Jun;25(4):438-42
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable outcome of photodynamic therapy for choroidal neovascularization associated with choroidal nevus.
  • PURPOSE: To report five cases of classic choroidal neovascularization (CNV) associated with choroidal nevus treated with photodynamic therapy (PDT) with verteporfin.
  • CONCLUSION: Bearing in mind that both the natural history and the post-PDT outcome may be extremely variable, further studies are needed to assess the real benefit of PDT for classic CNV secondary to choroidal nevus.
  • [MeSH-major] Choroid Neoplasms / complications. Choroidal Neovascularization / drug therapy. Choroidal Neovascularization / etiology. Nevus, Pigmented / complications. Photochemotherapy
  • [MeSH-minor] Aged. Capillary Permeability. Coloring Agents. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Middle Aged. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Retreatment. Retrospective Studies. Visual Acuity

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933589.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


42. Kim JJ, Chang MW, Shwayder T: Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus. J Am Acad Dermatol; 2000 Jul;43(1 Pt 1):129-32
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus.
  • Treatment of a linear verrucous epidermal nevus using topical 0.1% tretinoin cream and 5% 5-fluorouracil in a young patient is described.
  • In 1994, successful topical therapy using this combination was described in the management of an inflammatory linear verrucous epidermal nevus.
  • We report another case in which treatment of a noninflamed epidermal verrucous nevus with 0.1% tretinoin and 5% 5-fluorouracil resulted in significant improvement.
  • An updated summary of the literature discussing management of epidermal nevi is presented.
  • [MeSH-major] Antimetabolites / therapeutic use. Fluorouracil / therapeutic use. Hamartoma / drug therapy. Keratolytic Agents / therapeutic use. Skin Diseases / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Child. Drug Combinations. Humans. Male

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Verrucous nevus.
  • Genetic Alliance. consumer health - Epidermal nevus.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10863239.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Drug Combinations; 0 / Keratolytic Agents; 5688UTC01R / Tretinoin; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Weaver DT, Fisher RA, Newlands ES, Paradinas FJ: Amniotic tissue in complete hydatidiform moles can be androgenetic. J Pathol; 2000 May;191(1):67-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amniotic tissue in complete hydatidiform moles can be androgenetic.
  • The purpose of this study was to determine whether amniotic tissue found associated with cases of complete hydatidiform mole (CM) was genetically identical to the CM, and therefore part of the molar pregnancy, or genetically dissimilar to the CM, suggesting derivation from a twin pregnancy.
  • DNA was prepared from formalin-fixed, paraffin-embedded blocks of tissue containing both CM and amnion.
  • Maternal DNA was prepared from decidual tissue in the same blocks, or from a maternal blood sample.
  • Fluorescent microsatellite genotyping was carried out to determine the origin of both the CM and the amniotic tissue.
  • In one of six cases examined, the amniotic tissue was genetically different from the CM and was therefore likely to be derived from a twin pregnancy.
  • In the five remaining cases, the amniotic tissue was genetically identical to the CM and was likely to be derived from the same conceptus.
  • It is concluded that androgenetic CM can support the development of amniotic tissue and that some early embryonic development may occur in CM.
  • The presence of amnion, or other fetal tissues, associated with molar tissue should not therefore always be considered indicative of a diagnosis of partial mole (PM).
  • [MeSH-major] Amnion / pathology. Hydatidiform Mole / genetics. Hydatidiform Mole / pathology. Pregnancy, Multiple

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 John Wiley & Sons, Ltd.
  • (PMID = 10767721.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  •  go-up   go-down


44. Yamada T, Matsuda T, Kudo M, Yamada T, Moriwaki M, Nishi S, Ebina Y, Yamada H, Kato H, Ito T, Wake N, Sakuragi N, Minakami H: Complete hydatidiform mole with coexisting dichorionic diamniotic twins following testicular sperm extraction and intracytoplasmic sperm injection. J Obstet Gynaecol Res; 2008 Feb;34(1):121-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete hydatidiform mole with coexisting dichorionic diamniotic twins following testicular sperm extraction and intracytoplasmic sperm injection.
  • We present the first report of complete hydatidiform mole (HM) with coexisting dichorionic diamniotic twins.
  • In our case, paternal isodisomy in the molar tissue was confirmed by microsatellite analysis suggesting that it resulted from duplication of a haploid paternal genome following monospermic fertilization of an inactivated oocyte or from monospermic fertilization of an inactivated oocyte with a diploid sperm.
  • After the operation, chemotherapy was initiated for persistent trophoblastic disease.
  • [MeSH-major] Hydatidiform Mole / diagnosis. Twins. Ultrasonography, Prenatal. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Abortion, Induced. Adult. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Pregnancy. Sperm Injections, Intracytoplasmic

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226144.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


45. Van Eijkeren MA, Sijmons EA, Witteveen PO, Verhaar MJ, Sie-Go DM, Heintz AP: Treatment of metastatic invasive moles in two husband-side sisters-in-law. Case reports and review of literature. Eur J Gynaecol Oncol; 2001;22(6):406-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic invasive moles in two husband-side sisters-in-law. Case reports and review of literature.
  • PURPOSE OF INVESTIGATION: The treatment of "high risk" persistent trophoblastic disease (PTD) consists of poly-chemotherapy.
  • METHODS: We describe two cases of "high risk" PTD in two husband-side sisters-in-law, in which poly-chemotherapy was stopped after histology became available and showed invasive metastatic mole.
  • CONCLUSION: It should be stressed that treatment decisions should be made based on the concept of "high" or "low" risk PTD, but if histology becomes available, chemotherapy might be less aggressive in cases of invasive mole.
  • If invasive mole could be familiar through the paternal line remains unclear with the current knowledge of genetics in trophoblastic disease.
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Metastasis. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874069.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Pautier P, Ghione S, Brailly-Tabard S, Lhommé C, Morice P, Bidart JM: Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy? Hum Reprod; 2001 Nov;16(11):2434-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy?
  • BACKGROUND: The study was conducted to evaluate whether the detection of serum molecular forms of inhibin (A and B) could be useful for the diagnosis, prognosis and follow-up of placental tumours.
  • METHODS: A total of 17 patients with hydatidiform mole (n = 13), invasive mole (n = 1) or choriocarcinoma (n = 3) were studied; serum concentrations of inhibins A and B, human chorionic gonadotrophin (HCG) and its free beta subunit (HCGbeta) were measured before chemotherapy (after mole evacuation for eight patients) and also during the course of chemotherapy (for 10 patients).
  • RESULTS: After evacuation or before chemotherapy for refractory disease, serum inhibin A and B concentrations were found to be increased in 10/17 and 4/17 patients, when HCG and HCGbeta were high in all patients.
  • In 10 patients with a follow-up during treatment, nine had a high concentration of inhibin A which correlated with those of HCG and HCGbeta.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / blood. Choriocarcinoma / blood. Hydatidiform Mole / blood. Inhibins / blood. Uterine Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11679534.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / inhibin A; 0 / inhibin B; 57285-09-3 / Inhibins
  •  go-up   go-down


47. Mohammadjafari R, Abedi P, Belady S, Hamidehkho T, Razi T: A case of nephrotic syndrome associated with hydatiform mole. Rare Tumors; 2010;2(4):e61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of nephrotic syndrome associated with hydatiform mole.
  • The present case study is on a 16-year-old woman who was suffering from nephrotic syndrome after recovery from complete type of hydatiform mole.
  • In her past medical history she had a suction curettage for hydatiform mole.
  • After she received 4 courses chemotherapy, she completely recovered and βhCG has fallen from 12127 IU/L to under 10 IU/mL.
  • After six courses chemotherapy the symptoms of nephrotic syndrome and invasive mole diminished, she released from hospital and scheduled for follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Yonsei Med J. 2000 Jun;41(3):407-10 [10957899.001]
  • [Cites] Obstet Gynecol. 1975 Jan;45(1):1-8 [1167413.001]
  • [Cites] Medicine (Baltimore). 1981 Jul;60(4):267-76 [7242320.001]
  • [Cites] Am J Clin Pathol. 1981 Jul;76(1):109-12 [7258148.001]
  • [Cites] Kidney Int. 1978 Feb;13(2):166-77 [713277.001]
  • (PMID = 21234253.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019596
  • [Keywords] NOTNLM ; chemotherapy. / hydatiform mole / nephrotic syndrome
  •  go-up   go-down


48. Baasanjav B, Usui H, Kihara M, Kaku H, Nakada E, Tate S, Mitsuhashi A, Matsui H, Shozu M: The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles. Hum Reprod; 2010 May;25(5):1183-91
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles.
  • BACKGROUND: Complete hydatidiform mole (CHM) is a high-risk pregnancy for gestational trophoblastic neoplasia (GTN).
  • CHM includes androgenic homozygous (monospermic) and androgenic heterozygous (dispermic) moles.
  • Cytogenesis of the mole was determined by STR polymorphisms of molar tissue and parental blood.
  • The remaining mole was diandric triploidy (a partial hydatidiform mole).
  • Of the 24 homozygous CHMs, six (25%) cases developed GTN and received chemotherapy.
  • Meanwhile, all three cases (100%) of heterozygous mole developed GTN and needed chemotherapy.
  • The GTN risk was higher in heterozygous (P = 0.029, Fisher's exact test) than homozygous moles.
  • A systematic review revealed only five previous reports (with more than 15 cytogenetically diagnosed cases), and the pooled relative risk of persistent GTN for heterozygous mole was not significant (odds ratio, 2.0; 95% confidence interval, 0.98-4.07).
  • [MeSH-major] Hydatidiform Mole / genetics. Uterine Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208060.001).
  • [ISSN] 1460-2350
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


49. Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E, Staiano A: Blue rubber bleb nevus syndrome. Acta Paediatr; 2010 Apr;99(4):632-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blue rubber bleb nevus syndrome.
  • Blue Rubber Bleb Nevus Syndrome (BRBNS) is a rare condition characterized by multiple venous malformations involving the skin and internal organs.
  • Endoscopy is the gold standard technique for the diagnosis of BRBNS with GI lesions and also allows immediate therapeutic measures such as argon plasma coagulation, laser photocoagulation, sclerotherapy or band ligation.
  • In addition, pharmacological treatments based on corticosteroids, interferon alfa, vincristine or octreotide have been described for BRBNS.
  • CONCLUSION: Blue Rubber Bleb Nevus Syndrome is a congenital cutaneous and gastrointestinal haemangiomatosis.
  • The treatment is based on pharmacological or surgical therapy.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Hemangioma / pathology. Nevus, Blue / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Blue Rubber Bleb Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958301.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


50. Kerkmeijer L, Wielsma S, Bekkers R, Pyman J, Tan J, Quinn M: Guidelines following hydatidiform mole: a reappraisal. Aust N Z J Obstet Gynaecol; 2006 Apr;46(2):112-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines following hydatidiform mole: a reappraisal.
  • OBJECTIVE: The aim of this study was to determine how often patients with complete hydatidiform mole (CHM) who spontaneously achieve normal human chorionic gonadotrophin (hCG) levels subsequently develop persistent or recurrent gestational trophoblast disease.
  • METHODS: Four hundred and fourteen cases of CHM registered at the Hydatidiform Mole Registry of Victoria were reviewed retrospectively after molar evacuation.
  • Maternal age, gestational age, gravidity and parity were determined for each patient, as well as the need for chemotherapy.
  • RESULTS: Among the 414 patients, 55 (13.3%) required chemotherapy for persistent trophoblastic disease.
  • None of the patients whose hCG levels spontaneously fell to normal subsequently developed persistent molar disease.
  • [MeSH-major] Chorionic Gonadotropin / blood. Hydatidiform Mole / diagnosis. Neoplasm Recurrence, Local / diagnosis. Practice Guidelines as Topic. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Maternal Age. Monitoring, Physiologic / standards. Parity. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy. Pregnancy Outcome. Registries. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Aust N Z J Obstet Gynaecol. 2006 Jun;46(3):179. Wiesma, Sabien [corrected to Wielsma, Sabien]
  • (PMID = 16638032.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin
  •  go-up   go-down


51. Horn LC, Kowalzik J, Bilek K, Richter CE, Einenkel J: Prognostic value of trophoblastic proliferation in complete hydatidiform moles in predicting persistent disease. Pathol Res Pract; 2006;202(3):151-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of trophoblastic proliferation in complete hydatidiform moles in predicting persistent disease.
  • The clinical outcome of patients with complete hydatidiform moles (CHM) is variable.
  • The need for chemotherapy and occurrence of metastatic disease was correlated with the histologic grade using a three-level score.
  • Twelve out of 151 cases were re-evaluated as hydropic abortion, partial moles, or were insufficient for morphologic examination, representing a diagnostic agreement of 92%.
  • Twenty-six of the CHM (19%) required chemotherapy.
  • Grade 3, on histology, showed a positive correlation with the necessity of chemotherapy (p=0.04), but not with the occurrence of metastatic disease.
  • [MeSH-major] Hydatidiform Mole / diagnosis. Trophoblasts / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Proliferation. Chorionic Gonadotropin / metabolism. Diagnosis, Differential. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis / pathology. Pregnancy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436315.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


52. Deliduka SB, Kwong PC: Treatment of Nevus comedonicus with topical tazarotene and calcipotriene. J Drugs Dermatol; 2004 Nov-Dec;3(6):674-6
Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Nevus comedonicus with topical tazarotene and calcipotriene.
  • Nevus comedonicus is a rare developmental defect of the pilosebaceous unit.
  • It is also thought to be a variant of epidermal nevus.
  • Previously reported treatments include surgical excision, CO2 laser, dermabrasion, extraction, topical retinoic acid, and numerous topical keratolytics.
  • We present a case of a 7-year-old boy with bilateral nevus comedonicus who experienced cosmetic improvement with topical tazarotene and calcipotriene cream.
  • This combination represents a novel therapeutic approach to the treatment of this cutaneous abnormality.
  • [MeSH-major] Calcitriol / analogs & derivatives. Facial Dermatoses / drug therapy. Nevus, Pigmented / drug therapy. Sweat Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Child. Dermatologic Agents / administration & dosage. Diagnosis, Differential. Drug Therapy, Combination. Humans. Male. Nicotinic Acids / administration & dosage

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624751.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Nicotinic Acids; 143NQ3779B / calcipotriene; 81BDR9Y8PS / tazarotene; FXC9231JVH / Calcitriol
  •  go-up   go-down


53. Guldbakke KK, Khachemoune A, Deng A, Sina B: Naevus comedonicus: a spectrum of body involvement. Clin Exp Dermatol; 2007 Sep;32(5):488-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Naevus comedonicus: a spectrum of body involvement.
  • Naevus comedonicus (NC) is a rare developmental anomaly, with < 200 cases reported in the literature.
  • We review the current literature, emphasizing the clinical features, associated conditions and therapeutic options.
  • [MeSH-major] Nevus / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dermabrasion / methods. Dermatologic Agents / therapeutic use. Female. Humans. Male. Rare Diseases / drug therapy. Rare Diseases / pathology. Rare Diseases / surgery

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509056.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents
  • [Number-of-references] 34
  •  go-up   go-down


54. Hancock BW, Nazir K, Everard JE: Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J Reprod Med; 2006 Oct;51(10):764-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome.
  • OBJECTIVE: To report the Sheffield experience with persistent gestational trophoblastic neoplasia (GTN) after partial hydatidiform mole (PHM) and to review worldwide experience.
  • Clinical features, treatment and outcome were recorded.
  • Forty-one developed persistent GTN.
  • During the same period, 271 cases of persistent GTN originally registered as complete hydatidiform mole were reviewed; 3 were found to be PHMs (2 low, 1 high risk).
  • In all, 15 of 17 persistent PHMs required chemotherapy.
  • CONCLUSION: Persistent GTN requiring chemotherapy can occasionally occur after PHM; surveillance of all cases continues to be recommended.
  • [MeSH-major] Hydatidiform Mole / epidemiology. Neoplasm Recurrence, Local / epidemiology. Uterine Neoplasms / epidemiology
  • [MeSH-minor] England / epidemiology. Female. Humans. Incidence. Medical Records. Pregnancy. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17086803.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Scott JX, Krishnan S, Bourne AJ, Williams MP, Agzarian M, Revesz T: Treatment of metastatic sialoblastoma with chemotherapy and surgery. Pediatr Blood Cancer; 2008 Jan;50(1):134-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic sialoblastoma with chemotherapy and surgery.
  • We present a case of sialoblastoma with lung metastases that developed in a 4-year-old girl adjacent to a congenital nevus in the left cheek.
  • The patient responded well to chemotherapy and underwent surgical excision of the primary tumor, followed by three more courses of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / secondary. Parotid Neoplasms / pathology. Pneumonectomy
  • [MeSH-minor] Child, Preschool. Facial Neoplasms / pathology. Female. Humans. Neoplasms, Multiple Primary / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16514617.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Shen DH, Khoo US, Ngan HY, Ng TY, Chau MT, Xue WC, Cheung AN: Coexisting epithelioid trophoblastic tumor and choriocarcinoma of the uterus following a chemoresistant hydatidiform mole. Arch Pathol Lab Med; 2003 Jul;127(7):e291-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexisting epithelioid trophoblastic tumor and choriocarcinoma of the uterus following a chemoresistant hydatidiform mole.
  • The epithelioid trophoblastic tumor is an unusual type of trophoblastic tumor.
  • The patient had a history of hydatidiform mole with recurrent elevation of human chorionic gonadotrophin level that is resistant to chemotherapy.
  • The development of epithelioid trophoblastic tumor may be related to the persistence of locally invasive disease, which was unresponsive to chemotherapy.
  • [MeSH-major] Choriocarcinoma. Chorionic Gonadotropin / blood. Drug Resistance, Neoplasm. Epithelioid Cells / pathology. Hydatidiform Mole / drug therapy. Trophoblastic Neoplasms. Uterine Neoplasms

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12823059.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


57. Kerkmeijer LG, Wielsma S, Massuger LF, Sweep FC, Thomas CM: Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands. Gynecol Oncol; 2007 Jul;106(1):142-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
  • OBJECTIVES: To determine the risk for recurrent trophoblastic disease after spontaneous normalization of human chorionic gonadotropin (hCG) levels in patients with hydatidiform mole and to determine the risk for tumor relapse after apparent remission following chemotherapy in patients with low- and high-risk persistent trophoblastic disease.
  • METHODS: From 1994 until 2004, 355 patients with hydatidiform mole were registered at the Dutch Central Registry of Hydatidiform Mole and were monitored by sequential hCG assays in serum at the department of Chemical Endocrinology of the Radboud University Nijmegen Medical Centre.
  • HCG regression curves were analyzed together with clinical information collected from the Hydatidiform Mole Database.
  • RESULTS: Among the 355 registered hydatidiform mole patients, 265 patients attained spontaneous normalization following evacuation.
  • Of the 265 patients, one patient (0.38%) subsequently required chemotherapeutic treatment for recurrent trophoblastic disease (95% confidence interval 0.0% to 2.1%).
  • CONCLUSION: Our analysis indicates that relapse risk in hydatidiform mole patients with spontaneous normalization is extremely low (one in 265 patients) after two normal hCG levels (<2.0 ng/ml) are achieved.
  • Our results support the suggestion that two subsequent normal hCG levels may be sufficient to ensure sustained remission after hydatidiform mole evacuation.
  • In contrary, in order to assure sustained remission, the relapse rates after chemotherapy in the current study emphasize the need for surveillance of trophoblastic tumor patients even after complete remission has apparently been achieved.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / blood. Hydatidiform Mole / blood. Neoplasm Recurrence, Local / blood. Trophoblastic Neoplasms / blood. Uterine Neoplasms / blood

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462723.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


58. Lurain JR: Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol; 2010 Dec;203(6):531-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole.
  • Gestational trophoblastic disease includes hydatidiform mole (complete and partial) and gestational trophoblastic neoplasia (invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor).
  • Particular emphasis is given to management of hydatidiform mole, including evacuation, twin mole/normal fetus pregnancy, prophylactic chemotherapy, and follow-up.
  • [MeSH-major] Gestational Trophoblastic Disease / drug therapy. Gestational Trophoblastic Disease / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Abortion, Therapeutic / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / diagnosis. Choriocarcinoma / drug therapy. Choriocarcinoma / mortality. Choriocarcinoma / pathology. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hydatidiform Mole / drug therapy. Hydatidiform Mole / pathology. Hysterectomy / methods. Pregnancy. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20728069.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


59. In SI, Lee JY, Kim YC: Topical photodynamic therapy for nevus sebaceous on the face. Eur J Dermatol; 2010 Sep-Oct;20(5):590-2
Genetic Alliance. consumer health - Nevus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical photodynamic therapy for nevus sebaceous on the face.
  • Recently, topical photodynamic therapy (PDT) has been tried to treat sebaceous gland disorders.
  • However, only one case of nevus sebaceous treated with PDT has been reported.
  • Our aim was to investigate the outcomes of PDT on nevus sebaceus on the face.
  • Clinical improvement was visually assessed at 1 month after treatment by the lesional responses; No response was defined as less than 25%, mild improvement as 25-50%, moderate improvement as 51-75% and marked improvement as more than 75% decrease of lesional volume.
  • However, 2 patients showed partial recurrences after completion of treatment.
  • There was no significant side effect.These results suggest that topical PDT may be considered as an effective alternative treatment modality of nevus sebaceous on the face.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Nevus, Sebaceous of Jadassohn / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Face. Female. Humans. Male. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20709645.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


60. Hosalkar HS, Jones DH, Offiah A, Hall C: Linear sebaceous naevus syndrome and resistant rickets. J Bone Joint Surg Br; 2003 May;85(4):578-83
Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear sebaceous naevus syndrome and resistant rickets.
  • The association between vitamin-D-resistant rickets and linear sebaceous naevus syndrome is extremely rare.
  • The disturbances of metabolism of vitamin D and the effects of pharmacological treatment are also described.
  • [MeSH-major] Hypophosphatemia, Familial / complications. Nevus / complications. Sebaceous Gland Neoplasms / complications
  • [MeSH-minor] Calcitriol / therapeutic use. Child. Child, Preschool. Humans. Leg / radiography. Male. Pelvic Bones / radiography. Phosphates / therapeutic use. Syndrome

  • Genetic Alliance. consumer health - Rickets.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Bone Joint Surg Br. 2004 Jan;86(1):151; author reply 151 [14765888.001]
  • (PMID = 12793567.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Phosphates; FXC9231JVH / Calcitriol
  •  go-up   go-down


61. Schoeberl MR: A model for the behavior of beta-hCG after evacuation of hydatidiform moles. Gynecol Oncol; 2007 Jun;105(3):776-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A model for the behavior of beta-hCG after evacuation of hydatidiform moles.
  • OBJECTIVES: The objective of this study is to develop a physical model of the behavior of beta-hCG following the complete evacuation of a hydatidiform mole.
  • Because hCG is an excellent marker for continued trophoblastic activity, the model can be used for early detection of persistent sites.
  • METHOD: The model was developed from analysis of the post surgical hCG decrease in a patient with Stage III gestational trophoblastic neoplasia.
  • In contrast to those studies, however, we assume that the decrease can be explained by the dilution of the residual hCG from two different tissue reservoirs, a tissue reservoir with a half-life of approximately 4 days and a reservoir with a longer half-life, in this case approximately 18 days.
  • RESULTS: Simple dilution of two tissue reservoirs explains behavior of hCG following tumor removal.
  • The model also explains the hCG decrease in a larger study of Japanese and Dutch women following the evacuation of uneventful hydatidiform moles.
  • CONCLUSIONS: Following an initial rapid drop in hCG after resolution of the mole, the patient should experience a slower drop associated with the dilution of residual hCG in the deep tissue reservoir.
  • The physical model suggests that even earlier detection of chemotherapy resistant persistent trophoblastic disease is possible if the patient's decrease in hCG is slower than a log-linear fit to the patient's previous data.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / metabolism. Hydatidiform Mole / metabolism. Models, Biological. Uterine Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395254.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


62. Dòmini M, Aquino A, Fakhro A, Tursini S, Marino N, Di Matteo S, Lelli Chiesa P: Blue rubber bleb nevus syndrome and gastrointestinal haemorrhage: which treatment? Eur J Pediatr Surg; 2002 Apr;12(2):129-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blue rubber bleb nevus syndrome and gastrointestinal haemorrhage: which treatment?
  • PURPOSE: To describe a paediatric case of "Blue Rubber Bleb Nevus Syndrome" (BRBNS) or Bean's syndrome, a rare systemic disorder characterised by cutaneous and gastrointestinal vascular malformations that often lead to overt life-threatening gastrointestinal bleeding or occult blood loss with severe anaemia and iron deficiency.
  • A few months previously she was endoscopically treated for gastric angiomas which developed into melaena.
  • Most of the time it occurs sporadically, but it can be inherited as an autosomal dominant trait.
  • BRBNS patients present typical skin lesions, with some lesions having a rubber-like nipple appearance; the number of skin and GI lesions and the severity of anaemia are correlated.
  • Treatment is dependent on the extent of gut involvement and the severity of the clinical picture.
  • In the absence of massive bleeding, a conservative treatment will be sufficient; otherwise resections are mandatory, but additional lesions may subsequently develop.
  • Pharmacological treatment is useless.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Gastrointestinal Neoplasms / surgery. Hemangioma / surgery. Nevus, Blue / surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Blue Rubber Bleb Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12015660.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Takahashi Y, Murota H, Tarutani M, Sano S, Okinaga T, Tominaga K, Yano T, Katayama I: A case of juvenile dermatomyositis manifesting inflammatory epidermal nevus-like skin lesions: unrecognized cutaneous manifestation of blaschkitis? Allergol Int; 2010 Dec;59(4):425-8
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of juvenile dermatomyositis manifesting inflammatory epidermal nevus-like skin lesions: unrecognized cutaneous manifestation of blaschkitis?
  • BACKGROUND: Juvenile dermatomyositis is potentially life threatening rare autoimmune illness that mainly affects muscle and skin.
  • CASE SUMMARY: We report an 8-year-old male juvenile dermatomyositis who presented epidermal nevus like-lesions on the back of the right thigh.
  • However, epidermal nevus-like skin lesions, an acquired inflammatory dermatosis that follows Blaschko lines, seen in this case have been rarely reported in the literatures.
  • [MeSH-major] Muscle Tonus / immunology. Muscle, Skeletal / pathology. Skin / pathology
  • [MeSH-minor] Biopsy. Child. Child, Preschool. Dermatomyositis / diagnosis. Dermatomyositis / drug therapy. Dermatomyositis / pathology. Dermatomyositis / physiopathology. Erythema. Humans. Immunoglobulin E / blood. Inflammation. Keratoderma, Palmoplantar. Male. Nevus, Sebaceous of Jadassohn. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Juvenile dermatomyositis.
  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Epidermal nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Allergol Int. 2011 Sep;60(3):401 [21502807.001]
  • (PMID = 20962570.001).
  • [ISSN] 1440-1592
  • [Journal-full-title] Allergology international : official journal of the Japanese Society of Allergology
  • [ISO-abbreviation] Allergol Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 37341-29-0 / Immunoglobulin E; 9PHQ9Y1OLM / Prednisolone; Amyopathic dermatomyositis
  •  go-up   go-down


64. Feng FZ, Xiang Y, Shan Y, Wan XR, Oang XY: [Clinical analysis of patients with lung metastasis of invasive mole before evacuation of hydatidiform mole]. Zhonghua Fu Chan Ke Za Zhi; 2007 Dec;42(12):830-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of patients with lung metastasis of invasive mole before evacuation of hydatidiform mole].
  • OBJECTIVE: To investigate the clinical characteristics, management and outcome of patients with lung metastasis of invasive mole (IM) before evacuation of hydatidiform mole (HM).
  • METHODS: Clinical data of patients with hydatidiform mole (HM) and lung metastasis of IM who were diagnosed and treated at Peking Union Medical College Hospital from Jan 2004 to Jan 2006 were analyzed retrospectively.
  • Also, no statistically significant differences between positive group and control group were noted in the complete resolution rate achieved, the average courses of resolution of serum beta-hCG level and disappearance or marked absorption of lung metastasis needed, and the total chemotherapy courses (P > 0.05).
  • CONCLUSIONS: Once HM is diagnosed, evacuation should be performed as soon as possible, the later the evacuation begins, the higher the risks of lung metastasis and chemotherapy are.
  • It is not necessary to worry about lung metastasis before evacuation of HM, the outcome of post-chemotherapy is very good.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / metabolism. Hydatidiform Mole / pathology. Hydatidiform Mole, Invasive / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476517.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


65. Magnúsdóttir V, Stefánsson E: [Choroidal haemangioma worsens after laser therapy for skin port-wine nevus and improves with photodynamic therapy in the eye]. Laeknabladid; 2007 Feb;93(2):119-21
MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal haemangioma worsens after laser therapy for skin port-wine nevus and improves with photodynamic therapy in the eye].
  • A young man with facial port-wine nevus on one side of his face underwent skin laser treatment on his facial lesions and experienced worsening visual acuity from 0.9 to 0.4 and metamorphosis afterwards in the ipsilateral eye.
  • He received photodynamic therapy resulting in resolution of subretinal fluid and shrinkage of the haemangioma.
  • Visual acuity decreased to 0.1 one week following photodynamic treatment, but improved steadily after that.
  • Nine months following the treatment the visual acuity is 0.5 and metamorphosis is absent.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Laser Therapy / adverse effects. Photochemotherapy. Port-Wine Stain / surgery. Vision Disorders / etiology. Visual Acuity / radiation effects
  • [MeSH-minor] Humans. Male. Retinal Detachment / etiology. Tomography, Optical Coherence. Treatment Outcome

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277408.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


66. Uberti EM, Diestel MC, Guimarães FE, De Nápoli G, Schmid H: Single-dose actinomycin D: Efficacy in the prophylaxis of postmolar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole. Gynecol Oncol; 2006 Aug;102(2):325-32
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-dose actinomycin D: Efficacy in the prophylaxis of postmolar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole.
  • OBJECTIVE: To evaluate the efficacy of a single prophylactic dose of actinomycin D (Act-D) in the reduction of postmolar gestational trophoblastic neoplasia (GTN) in adolescents with high-risk hydatidiform mole (Hr-HM).
  • Twenty-nine received a single dose of Act-D at the time of uterine evacuation as prophylactic chemotherapy (P-chem) (study group) and 31 patients with the same risk factors did not received P-chem (control group).
  • Since this regimen may reduce treatment costs, without affecting compliance with follow-up, it can be adopted by any Trophoblastic Disease Center.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dactinomycin / therapeutic use. Gestational Trophoblastic Disease / prevention & control. Hydatidiform Mole / surgery

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476471.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


67. Hansen LF, Wewer V, Pedersen SA, Matzen P, Paerregaard A: Severe blue rubber bleb nevus syndrome in a neonate. Eur J Pediatr Surg; 2009 Feb;19(1):47-9
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe blue rubber bleb nevus syndrome in a neonate.
  • We report on a child with blue rubber bleb nevus syndrome (BRBNS) presenting during the first days of life with severe bleeding from the upper gastrointestinal tract.
  • Medical treatment with methylprednisolone, cyklokapron, interferon 1 alpha and numerous blood transfusions were given to control bleeding during the first 3 years of life.
  • At ten years of age the patient developed spastic diplegia with slight walking disabilities, coordination and fine motor problems.
  • [MeSH-major] Arteriovenous Malformations / surgery. Electrocoagulation / methods. Gastrointestinal Hemorrhage / surgery. Gastroscopy. Nevus, Blue. Skin Neoplasms / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Antifibrinolytic Agents / therapeutic use. Drug Therapy, Combination. Glucocorticoids / therapeutic use. Hemangioma / surgery. Humans. Immunologic Factors / therapeutic use. Infant, Newborn. Interferon-alpha / therapeutic use. Male. Methylprednisolone / therapeutic use. Syndrome. Tranexamic Acid / therapeutic use. Treatment Outcome


68. Shiina H, Oka K, Okane M, Tanno W, Kawasaki T, Nakayama M: Coexisting true hermaphroditism and partial hydatidiform mole developing metastatic gestational trophoblastic tumors. A case report. Virchows Arch; 2002 Nov;441(5):514-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexisting true hermaphroditism and partial hydatidiform mole developing metastatic gestational trophoblastic tumors. A case report.
  • We report a fetal autopsy case that was diagnosed with a mole coexistent with a live fetus at an early gestation and finally showed coexisting true hermaphroditism of 46,XX/46,XY mosaicism and partial hydatidiform mole, developing metastatic gestational trophoblastic tumors in the lungs of the mother.
  • A 23-year-old Japanese female had a mole coexistent with a fetus and showed a high chorionic gonadotropin titer in urine and serum at 10 weeks of gestation.
  • A chromosome analysis demonstrated 46,XX and 46,XY mosaicism in both umbilical cord blood and mole samples.
  • The testis had seminiferous tubules containing primitive germ cells, immature Sertoli cells, and cytomegalic Leydig cells.
  • The patient presented multiple metastatic pulmonary tumors at 1 month after the interruption, and was treated with chemotherapy for the clinical diagnosis of gestational trophoblastic tumor metastases.
  • [MeSH-major] Disorders of Sex Development / pathology. Fetus / abnormalities. Hydatidiform Mole / pathology. Pregnancy Complications, Neoplastic / pathology. Trophoblastic Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Abortion, Therapeutic. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Mosaicism / genetics. Neoplasms, Multiple Primary. Pregnancy

  • Genetic Alliance. consumer health - Hermaphroditism.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12447683.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


69. Atten MJ, Ahmed S, Attar BM, Richter H 3rd, Mehta B: Massive pelvic hemangioma in a patient with blue rubber bleb nevus syndrome. South Med J; 2000 Nov;93(11):1122-5
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive pelvic hemangioma in a patient with blue rubber bleb nevus syndrome.
  • Blue rubber bleb nevus syndrome (BRBNS) is a rare disorder characterized by gastrointestinal and cutaneous hemangiomas.
  • [MeSH-major] Hemangioma / etiology. Nevus, Blue / complications. Pelvic Neoplasms / etiology
  • [MeSH-minor] Adult. Anemia, Iron-Deficiency / drug therapy. Anemia, Iron-Deficiency / etiology. Dietary Supplements. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iron / therapeutic use. Neoplasm Invasiveness. Rectum / pathology. Syndrome


70. Ji YI, Jung MH: Gastrointestinal bleeding caused by ileal metastasis of a tubal complete mole: a case report. J Womens Health (Larchmt); 2010 Jun;19(6):1217-20
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal bleeding caused by ileal metastasis of a tubal complete mole: a case report.
  • BACKGROUND: Tubal hydatidiform mole is known to be an extremely rare disease, moreover, gastrointestinal metastasis from an ectopic complete mole has never been reported.
  • She had undergone laparoscopic left salpingectomy for a tubal complete mole a month earlier.
  • An ileal invasion of mole was identified.
  • The patient received nine cycles of adjuvant methotrexate chemotherapy after small bowel resection and anastomosis.
  • She was been without recurrence 20 months after therapy.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Hydatidiform Mole / secondary. Ileal Neoplasms / secondary. Pregnancy, Tubal

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20392142.001).
  • [ISSN] 1931-843X
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Toth B, Roth K, Kunert-Keil C, Scholz C, Schulze S, Mylonas I, Friese K, Jeschke U: Glycodelin protein and mRNA is downregulated in human first trimester abortion and partially upregulated in mole pregnancy. J Histochem Cytochem; 2008 May;56(5):477-85
MedlinePlus Health Information. consumer health - Miscarriage.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycodelin protein and mRNA is downregulated in human first trimester abortion and partially upregulated in mole pregnancy.
  • We evaluated the expression of Gd protein and mRNA in first trimester decidual tissue of normal pregnancies and spontaneous abortion and hydatidiform moles.
  • In decidual tissue of abortion patients, Gd expression was significantly decreased compared with normal gestation, which was confirmed by in situ hybridization.
  • In mole pregnancy, an upregulation of Gd in the first 8 weeks of pregnancy was present.
  • Gd is a main product of decidual tissue in the first trimester of human pregnancy.
  • Therefore, we speculate that hCG could be one of the factors regulating Gd expression because hCG is downregulated in women with abortion and upregulated in mole pregnancy.
  • [MeSH-major] Abortion, Spontaneous / genetics. Down-Regulation. Gene Expression Regulation, Neoplastic. Glycoproteins / genetics. Hydatidiform Mole / genetics. Pregnancy Proteins / genetics. Pregnancy Trimester, First / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biotechnol. 2000 Jan;14(1):47-57 [10911614.001]
  • [Cites] Hum Reprod Update. 2007 Nov-Dec;13(6):581-90 [17626114.001]
  • [Cites] Mol Hum Reprod. 2002 Feb;8(2):142-8 [11818517.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Jun 10;108(2):199-202 [12781411.001]
  • [Cites] Histochem Cell Biol. 2003 May;119(5):345-54 [12743827.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):1107-13 [12820356.001]
  • [Cites] Arch Gynecol Obstet. 2003 Aug;268(3):162-7 [12942243.001]
  • [Cites] Biol Reprod. 2003 Nov;69(5):1545-51 [12826581.001]
  • [Cites] Int J Gynaecol Obstet. 2004 May;85(2):105-18 [15099771.001]
  • [Cites] J Clin Endocrinol Metab. 1981 May;52(5):1006-8 [7014586.001]
  • [Cites] Biol Reprod. 1981 Oct;25(3):591-8 [6796144.001]
  • [Cites] Br J Obstet Gynaecol. 1985 Nov;92(11):1145-51 [4063232.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]
  • [Cites] Am J Reprod Immunol. 1991 Dec;26(4):137-42 [1840727.001]
  • [Cites] Fertil Steril. 1993 Jan;59(1):187-91 [8419206.001]
  • [Cites] Hum Reprod. 1993 Jun;8(6):793-8 [8345065.001]
  • [Cites] Glycobiology. 1994 Apr;4(2):221-5 [7519910.001]
  • [Cites] Hum Reprod. 1994 Jul;9(7):1339-43 [7962445.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):24116-26 [7592613.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(4):165-9 [8844133.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):32159-67 [8943270.001]
  • [Cites] FEBS Lett. 1998 Oct 9;436(3):455-60 [9801168.001]
  • [Cites] Cell Immunol. 1999 Jan 10;191(1):26-33 [9918684.001]
  • [Cites] J Mol Endocrinol. 1999 Aug;23(1):57-66 [10425447.001]
  • [Cites] J Perinat Med. 2005;33(3):212-8 [15914343.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jul;272(2):151-9 [15549334.001]
  • [Cites] Fertil Steril. 2006 Nov;86(5):1488-97 [17070198.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5378-88 [17192260.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3727-32 [11739178.001]
  • (PMID = 18256018.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Chorionic Gonadotropin; 0 / Glycoproteins; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2324189
  •  go-up   go-down


72. Mutasim DF: Successful treatment of inflammatory linear verrucous epidermal nevus with tacrolimus and fluocinonide. J Cutan Med Surg; 2006 Jan-Feb;10(1):45-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of inflammatory linear verrucous epidermal nevus with tacrolimus and fluocinonide.
  • BACKGROUND: Inflammatory linear verrucous epidermal nevus (ILVEN) is a relatively rare disorder that is characterized by an early age at onset; severely pruritic linear papules and plaques; histologic features resembling spongiotic dermatitis, psoriasis, or lichenified dermatitis; and poor response to treatment.
  • OBJECTIVE: To report the successful treatment of ILVEN with potent topical steroid and tacrolimus ointments.
  • She had failed treatment with pimecrolimus, calcipotriol, mometasone furoate, triamcinolone, tazarotene, and alpha-hydroxy acid.
  • CONCLUSION: The combination of two therapeutic agents with different mechanisms of action likely resulted in the successful treatment of this usually resistant condition.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Fluocinonide / therapeutic use. Immunosuppressive Agents / therapeutic use. Leg. Nevus / drug therapy. Skin Neoplasms / drug therapy. Tacrolimus / therapeutic use
  • [MeSH-minor] Child. Drug Therapy, Combination. Female. Humans


73. Kaye DK: Gestational trophoblastic disease following complete hydatidiform mole in Mulago Hospital, Kampala, Uganda. Afr Health Sci; 2002 Aug;2(2):47-51
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic disease following complete hydatidiform mole in Mulago Hospital, Kampala, Uganda.
  • OBJECTIVES: To determine epidemiological characteristics and clinical presentation of complete hydatidiform mole (CHM) and complications associated with prophylactic chemotherapy with oral methotrexate.
  • METHODS: Ninety-four patients with clinically and histologically confirmed complete hydatidiform mole admitted between 1/9/1995 and 30/1/1998 were followed for periods ranging from 12 months to 30 months.
  • Seventy-eight (83.0%) received a total of 187 courses of oral methotrexate (0.4 mg/kg daily in 3 divided doses) as prophylactic chemotherapy.
  • Twenty-four of the seventy-eight patients (30.7%) developed complications, mainly mucositis and haematological toxicity (leucopenia, anaemia and thrombocytopenia), commonly after 3 or more courses.
  • Oral methotrexate for prophylactic chemotherapy was tolerable and safe for the first 2 courses, but serious complications occur as the duration of treatment increases.
  • Those on prophylactic chemotherapy require close monitoring for the toxic effects of the drugs.
  • [MeSH-major] Hydatidiform Mole / epidemiology. Methotrexate / administration & dosage. Uterine Neoplasms / epidemiology. Uterine Neoplasms / prevention & control
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Age Distribution. Antimetabolites, Antineoplastic / administration & dosage. Female. Humans. Incidence. Middle Aged. Pregnancy. Pregnancy Outcome. Prospective Studies. Recurrence. Survival Analysis. Treatment Outcome. Uganda / epidemiology

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Obstet Gynaecol. 1970 May;10(2):109-11 [5274331.001]
  • [Cites] Am J Obstet Gynecol. 1973 Oct 1;117(3):341-4 [4354113.001]
  • [Cites] Am J Obstet Gynecol. 1982 Feb 15;142(4):416-9 [6277194.001]
  • [Cites] Cancer Res. 1983 May;43(5):2342-5 [6572562.001]
  • [Cites] Obstet Gynecol. 1984 Feb;63(2):140-4 [6320076.001]
  • [Cites] Clin Obstet Gynecol. 1984 Mar;27(1):211-20 [6323079.001]
  • [Cites] Int J Gynaecol Obstet. 1996 Mar;52(3):233-6 [8775674.001]
  • [Cites] Am J Obstet Gynecol. 1987 Nov;157(5):1166-8 [2825524.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Dec;94(12):1123-35 [3322372.001]
  • [Cites] Obstet Gynecol. 1988 Aug;72(2):247-51 [2455880.001]
  • [Cites] Int J Gynaecol Obstet. 1990 Aug;32(4):359-67 [1977631.001]
  • [Cites] Am J Obstet Gynecol. 1995 Feb;172(2 Pt 1):574-9 [7856688.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):624-9 [3015368.001]
  • (PMID = 12789101.001).
  • [ISSN] 1680-6905
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2141569
  •  go-up   go-down


74. Kashimura Y, Tanaka M, Harada N, Shinmoto M, Morishita T, Morishita H, Kashimura M: Twin pregnancy consisting of 46, XY heterozygous complete mole coexisting with a live fetus. Placenta; 2001 Apr;22(4):323-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twin pregnancy consisting of 46, XY heterozygous complete mole coexisting with a live fetus.
  • Complete hydatidiform mole and coexistent fetus (CMCF) is a rare occurrence and is associated with an increased risk of persistent gestational trophoblastic diseases.
  • Molar tissues are cytogenetically divided into two types, homozygous and heterozygous.
  • The molar tissue of our case showed a 46, XY heterozygous complete mole.
  • The patient developed persistent trophoblastic disease (PTD) with lung metastasis.
  • Nine of the 16 CMCF cases before 21 weeks of gestation and seven of the 12 CMCF cases after 22 weeks of gestation developed PTD.
  • There were 10 case reports that analyzed the zygosity of a mole, heterozygous or homozygous.
  • Two of six homozygous and three of four heterozygous moles in CMCF cases developed PTD.
  • A heterozygous mole is thought to be a high risk factor for the incidence of PTD.
  • [MeSH-major] Hydatidiform Mole / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chorionic Gonadotropin, beta Subunit, Human / blood. DNA / analysis. Female. Genotype. Gestational Age. Heterozygote. Humans. Karyotyping. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Methotrexate / therapeutic use. Polymerase Chain Reaction. Pregnancy. Pregnancy, Multiple. Tomography, X-Ray Computed. Trophoblastic Neoplasms / etiology. Twins. Ultrasonography, Prenatal. Uterine Neoplasms / etiology

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Harcourt Publishers Ltd.
  • (PMID = 11286568.001).
  • [ISSN] 0143-4004
  • [Journal-full-title] Placenta
  • [ISO-abbreviation] Placenta
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin, beta Subunit, Human; 9007-49-2 / DNA; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


75. Prosperi Porta R, Cavazzana AO, Coppola S, Franco C, Camilli A, Patella A: Postchemotherapy late recurrence of non metastatic gestational trophoblastic disease following a partiale mole. A case report. Eur J Gynaecol Oncol; 2000;21(4):403-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postchemotherapy late recurrence of non metastatic gestational trophoblastic disease following a partiale mole. A case report.
  • The authors describe a case of a 35-year-old woman who showed elevation of betahCG 13 months after the complete regression of betahCG values following chemotherapy for an incomplete mole.
  • This case outlines the necessity for careful monitoring of betahCG levels in low risk gestational trophoblastic diseases for a period of time longer than one year after achieving the first clinical remission.
  • [MeSH-major] Abortion, Spontaneous. Chorionic Gonadotropin, beta Subunit, Human / blood. Hydatidiform Mole / pathology. Neoplasm Recurrence, Local / diagnosis. Pregnancy Complications, Neoplastic / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Miscarriage.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11055495.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


76. Kim CH, Kim YH, Kim JW, Kim KM, Cho MK, Kim SM, Nam JH, Song TB: Triplet pregnancy with partial hydatidiform mole coexisting with two fetuses: a case report. J Obstet Gynaecol Res; 2008 Aug;34(4 Pt 2):641-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triplet pregnancy with partial hydatidiform mole coexisting with two fetuses: a case report.
  • Hydatidiform mole with a coexistent fetus is rare, but this condition has recently shown an increased incidence because of assisted reproduction technology.
  • Herein, we report on a case of triplet pregnancy with a partial hydatidiform mole coexisting with two fetuses.
  • Six courses of methotrexate chemotherapy were performed.
  • [MeSH-major] Hydatidiform Mole / diagnosis. Pregnancy, Multiple. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840171.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cyclin-Dependent Kinase Inhibitor p57
  •  go-up   go-down


77. Levy J, Shneck M, Klemperer I, Lifshitz T: Treatment of subfoveal choroidal neovascularization secondary to choroidal nevus using photodynamic therapy. Ophthalmic Surg Lasers Imaging; 2005 Jul-Aug;36(4):343-5
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of subfoveal choroidal neovascularization secondary to choroidal nevus using photodynamic therapy.
  • A 52-year-old man sought treatment for decreased vision in his right eye for 3 weeks.
  • Examination revealed an elevated choroidal nevus at the posterior pole.
  • The patient was treated by two sessions of photodynamic therapy with verteporfin.
  • Seven months after the last treatment, visual acuity remains stable.
  • Photodynamic therapy with verteporfin could be an effective option for treating subfoveal choroidal neovascularization secondary to choroidal nevus.
  • [MeSH-major] Choroid Neoplasms / complications. Choroidal Neovascularization / drug therapy. Choroidal Neovascularization / etiology. Nevus, Pigmented / complications. Photochemotherapy
  • [MeSH-minor] Coloring Agents. Fluorescein Angiography. Fovea Centralis. Humans. Indocyanine Green. Male. Middle Aged. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Visual Acuity

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16156155.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


78. Hu W, Nelson JE, Mohney CA, Willen MD: Malignant melanoma arising in a pregnant African American woman with a congenital blue nevus. Dermatol Surg; 2004 Dec;30(12 Pt 2):1530-2
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma arising in a pregnant African American woman with a congenital blue nevus.
  • BACKGROUND: The incidence of cutaneous melanoma in African-Americans is relatively low.
  • Despite the slightly greater occurrence of congenital melanocytic nevi in black persons compared with white persons, the cumulative risk of melanoma arising in these lesions is very small.
  • In addition, the overwhelming majority of melanomas in black persons occur on nonglaborous skin where congenital melanocytic nevi are rare.
  • OBJECTIVE: The objective was to describe and an unusual case of melanoma arising in a congenital nevus with combined features of a blue nevus on the scalp of a pregnant African-American woman.
  • RESULTS: Histologic examination revealed a polypoid malignant melanoma arising in association with a congenital blue nevus in a young African-American woman.
  • Pathology from parotidectomy and neck dissection confirmed metastatic melanoma involving two intraparotid lymph nodes and 3 of 26 cervical lymph nodes.
  • Despite aggressive chemotherapy, she died in 1 year after the diagnosis.
  • [MeSH-major] Melanoma / diagnosis. Nevus, Blue / congenital. Pregnancy Complications, Neoplastic / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606833.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Tsukihara S, Harada T, Terakawa N: Ultrasound-guided local injection of methotrexate to treat an invasive hydatidiform mole. J Obstet Gynaecol Res; 2004 Jun;30(3):202-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound-guided local injection of methotrexate to treat an invasive hydatidiform mole.
  • A 28-year-old Japanese woman had an invasive hydatidiform mole which was diagnosed by means of transvaginal ultrasonography.
  • After the two initial courses of systemic methotrexate (MTX) therapy given over a period of weeks, the tumor was 14 mm in diameter and the surrounding blood supply remained rich.
  • In addition to the two initial courses of systemic MTX therapy, local ultrasound-guided injection of MTX therapy was given three times, once per week.
  • After the local MTX treatment, the betahCG level, which had been as high as 240 ng/mL, dropped to less than 0.1 ng/mL.
  • We then gave two additional courses of systemic MTX therapy (once per week).
  • More than 3 years have passed since the final systemic MTX therapy, and the patient's serum betahCG levels continue to be less than 0.1 ng/mL.
  • An invasive mole can be treated with an ultrasound-guided local injection of MTX in addition to the established systemic MTX treatment.
  • [MeSH-major] Abortifacient Agents, Nonsteroidal / administration & dosage. Hydatidiform Mole / diagnosis. Hydatidiform Mole / drug therapy. Methotrexate / administration & dosage. Uterine Neoplasms / diagnosis. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gravidity. Humans. Injections, Intralesional. Neoplasm Invasiveness. Pregnancy. Ultrasonography, Interventional

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15210043.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Abortifacient Agents, Nonsteroidal; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


80. Limpongsanurak S: Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med; 2001 Feb;46(2):110-6
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic actinomycin D for high-risk complete hydatidiform mole.
  • OBJECTIVE: To evaluate the effectiveness of one course of prophylactic actinomycin D in reducing the malignant sequelae requiring chemotherapy in high-risk complete hydatidiform mole (CHM).
  • Within one week after evacuation of molar tissues, actinomycin D was administered in the chemoprophylactic group.
  • Patients in the control group were given only intravenous fluid and analgesic drugs.
  • The number of patients with malignant sequelae who required therapeutic chemotherapy after evacuation of hydatidiform mole in each group was recorded.
  • The side effects of prophylactic chemotherapy were stomatitis, nausea/vomiting, sore throat with oral ulcer and hair loss.
  • CONCLUSION: One course of actinomycin D given as chemoprophylaxis decreased by 72.4% malignant sequelae after evacuation of molar tissue in patients with high-risk CHM.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dactinomycin / therapeutic use. Hydatidiform Mole / prevention & control. Uterine Neoplasms / prevention & control
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Double-Blind Method. Female. Humans. Incidence. Pregnancy. Risk Factors

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11255809.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


81. True DK, Thomsett M, Liley H, Chitturi S, Cincotta R, Morton A, Cotterill A: Twin pregnancy with a coexisting hydatiform mole and liveborn infant: complicated by maternal hyperthyroidism and neonatal hypothyroidism. J Paediatr Child Health; 2007 Sep;43(9):646-8
Hazardous Substances Data Bank. PROPYL THIOURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twin pregnancy with a coexisting hydatiform mole and liveborn infant: complicated by maternal hyperthyroidism and neonatal hypothyroidism.
  • A twin pregnancy with a coexisting complete hydatiform mole and a healthy fetus is rare.
  • We describe a case of a woman, 23/40 pregnant, who was diagnosed with a twin pregnancy complicated by a hydatiform mole, vaginal bleeding, hyperthyroidism and preterm labour at 26/40.
  • The baby developed biochemical hypothyroidism post-natally.
  • [MeSH-major] Antithyroid Agents / adverse effects. Hyperthyroidism / drug therapy. Hypothyroidism / complications. Propylthiouracil / adverse effects
  • [MeSH-minor] Adrenergic beta-Antagonists / therapeutic use. Adult. Female. Humans. Hydatidiform Mole. Infant, Newborn. Live Birth. Male. Pregnancy. Propranolol / therapeutic use. Thyroid Function Tests. Treatment Outcome. Twins

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688651.001).
  • [ISSN] 1034-4810
  • [Journal-full-title] Journal of paediatrics and child health
  • [ISO-abbreviation] J Paediatr Child Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Antithyroid Agents; 721M9407IY / Propylthiouracil; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


82. van Trommel NE, Sweep FC, Schijf CP, Massuger LF, Thomas CM: Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios. Eur J Endocrinol; 2005 Oct;153(4):565-75
Genetic Alliance. consumer health - Hydatidiform mole.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios.
  • OBJECTIVE: Human chorionic gonadotropin (hCG) is widely used in the management of hydatidiform mole and persistent trophoblastic disease (PTD).
  • Predicting PTD after molar pregnancy might be beneficial since prophylactic chemotherapy reduces the incidence of PTD.
  • DESIGN: A retrospective study based on blood specimens collected in the Dutch Registry for Hydatidiform Moles.
  • A group of 165 patients with complete moles (of which 43 had PTD) and 39 patients with partial moles (of which 7 had PTD) were compared with 27 pregnant women with uneventful pregnancy.
  • METHODS: Serum samples from patients with hydatidiform mole with or without PTD were assayed using specific (radio) immunoassays for free alpha-subunit (hCGalpha), free beta-subunit (hCGbeta) and 'total' hCG (hCG + hCGbeta).
  • RESULTS: hCGbeta, hCGbeta/hCG + hCGbeta and hCGalpha/hCGbeta show AUCs ranging between 0.922 and 0.999 and, therefore, are excellent diagnostic tests to distinguish complete and partial moles from normal pregnancy.
  • To distinguish partial from complete moles the analytes hCGbeta, hCG + hCGbeta and the ratio hCGalpha/hCGbeta have AUCs between 0.7 and 0.8.
  • Although hCGalpha, hCGbeta and hCG + hCGbeta concentrations are significantly elevated in patients who will develop PTD compared with patients with spontaneous regression after evacuation of their moles, in predicting PTD, these analytes and parameters have AUCs <0.7.
  • CONCLUSIONS: Distinction between hydatidiform mole and normal pregnancy is best shown by a single blood specimen with hCGbeta, but hCGbeta/hCG + hCGbeta and hCGalpha/hCGbeta are also excellent diagnostic parameters.
  • To predict PTD, hCGalpha, hCGbeta, hCG + hCGbeta and hCGalpha/hCGbeta are moderately accurate tests, although they are not accurate enough to justify prophylactic chemotherapy treatment for prevention of PTD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189178.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Glycoprotein Hormones, alpha Subunit
  •  go-up   go-down


83. Adewole IF, Oladokun A, Fawole AO, Olawuyi JF, Adeleye JA: Fertility regulatory methods and development of complications after evacuation of complete hydatidiform mole. J Obstet Gynaecol; 2000 Jan;20(1):68-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility regulatory methods and development of complications after evacuation of complete hydatidiform mole.
  • In a prospective, simple randomised study, we evaluated the relative efficacy of hormonal (oral contraceptive pill) and non-hormonal (intrauterine contraceptive device) methods of contraception as fertility regulatory agents in patients with complete hydatidiform moles and assessed the development of complications and sequelae if any, following their use.
  • Five patients (two on OCP, and three on IUCD) developed a gestational trophoblastic tumour and were admitted for chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15512472.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


84. Murakami M, Wada T, Kashiwagi T, Ishida-Yamamoto A, Iizuka H: Nodular malignant melanoma with Spitz nevus-like pathological features finally confirmed by the pathological feature of the sentinel lymph node. J Dermatol; 2007 Dec;34(12):821-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular malignant melanoma with Spitz nevus-like pathological features finally confirmed by the pathological feature of the sentinel lymph node.
  • The clinical and histopathological similarities of nodular melanoma and Spitz nevus currently still make a definitive diagnosis difficult.
  • We report here a case of nodular melanoma that was extremely difficult to diagnose both clinically and histopathologically.
  • Although our first impression was malignant melanoma, we asked two dermatopathologists for second opinions; however, one diagnosed a melanoma and the other a Spitz nevus.
  • Histopathological diagnosis to establish whether it was a melanoma metastasis or nodal nevi was also difficult, and we again asked for second opinions from another dermatopathologist in the USA.
  • According to its clinical course and the histopathology of the sentinel lymph node with additional immunohistochemistry, this case was finally diagnosed as a nodular melanoma (T4aN1aM0, stage IIIA).
  • To date, the patient has been given five courses of chemotherapy at 6-month intervals, with no local recurrence or distant metastases so far.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Melanoma / pathology. Scalp. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Nevus, Epithelioid and Spindle Cell / pathology. Sentinel Lymph Node Biopsy


85. Sebire NJ, Foskett M, Paradinas FJ, Fisher RA, Francis RJ, Short D, Newlands ES, Seckl MJ: Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet; 2002 Jun 22;359(9324):2165-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin.
  • We assessed 77 twin pregnancies, comprising complete hydatidiform mole (CHM) and healthy co-twin, to ascertain the risks to the mother and baby of continuing the pregnancy, versus termination.
  • Chemotherapy to eliminate persistent gestational trophoblastic disease (pGTD) was required in three of 19 women (16%; 95% CI 3-39) who terminated their pregnancies in the first trimester, and in 12 of 58 (21%; 95% CI 11-33%) who continued their pregnancies.
  • [MeSH-major] Abortion, Spontaneous / etiology. Fetal Death / etiology. Hydatidiform Mole / complications. Pregnancy Complications, Neoplastic / physiopathology. Pregnancy Outcome. Twins. Uterine Neoplasms / complications


86. Bruchim I, Kidron D, Amiel A, Altaras M, Fejgin MD: Complete hydatidiform mole and a coexistent viable fetus: report of two cases and review of the literature. Gynecol Oncol; 2000 Apr;77(1):197-202
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete hydatidiform mole and a coexistent viable fetus: report of two cases and review of the literature.
  • OBJECTIVE: The aim of this study was to report the clinical features, management, and outcome of two cases of complete hydatidiform mole with a coexisting viable fetus and to review the literature.
  • PATIENTS: In this article, we report on the well-documented follow-up of 2 cases of twin pregnancies with complete hydatidiform mole and a viable fetus, both of which ended with the delivery of a normal infant at 41 and 26 weeks of gestation.
  • Since 1977, the year in which complete and partial moles were characterized as distinct pathologic entities, 15 cases (including our 2) have been reported.
  • RESULTS: Persistent GTT developed in eight patients (53.3%) and four patients (27.7%) developed metastatic disease.
  • Seventy-five percent patients with persistent GTT were treated with single-agent chemotherapy.
  • CONCLUSION: Complete hydatidiform mole and coexistent fetus is a rare occurrence and is associated with an increased risk of persistent gestational trophoblastic tumor.
  • [MeSH-major] Fetal Viability. Hydatidiform Mole / pathology. Pregnancy Complications, Neoplastic / pathology. Trophoblastic Neoplasms / etiology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • [CommentIn] Gynecol Oncol. 2000 Dec;79(3):524-5 [11104636.001]
  • (PMID = 10739712.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 19
  •  go-up   go-down


87. Sebire NJ, Seckl MJ: Immunohistochemical staining for diagnosis and prognostic assessment of hydatidiform moles: current evidence and future directions. J Reprod Med; 2010 May-Jun;55(5-6):236-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining for diagnosis and prognostic assessment of hydatidiform moles: current evidence and future directions.
  • OBJECTIVE: To review the published data on studies examining immunohistochemical markers of hydatidiform moles for determination of diagnosis or prognosis, with regard to whether such investigations can provide clinically relevant information.
  • STUDY DESIGN: Search of computerized literature databases to identify studies reporting on immunohistochemical findings in cases of hydatidiform mole followed by summarization and interpretation of the findings.
  • Some markers, such as P57(KIP2), show distinct differences in expression between groups and are useful in clinical practice for the diagnosis of complete hydatidiform moles.
  • Some markers appear to be associated with increased risk of progression to requiring chemotherapy, including increased expression of P53, EGFR, HER2, c-erbB-2 and telomerase and reduced expression of nm23.
  • CONCLUSION: Despite technical issues complicating overall interpretation, such as small sample size and the uncertainty of classification of hydatidiform moles in many studies, convincing data is reported for several markers, which should guide future studies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Hydatidiform Mole / diagnosis. Uterine Neoplasms / diagnosis


88. De Vos M, Leunen M, Fontaine C, De Sutter P: Successful Primary Treatment of a Hydatidiform Mole with Methotrexate and EMA/CO. Case Rep Med; 2009;2009:454161
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful Primary Treatment of a Hydatidiform Mole with Methotrexate and EMA/CO.
  • Background. The preferred treatment method of most hydatidiform moles is suction aspiration.
  • In rare circumstances uterine abnormalities may preclude surgical treatment. Case.
  • A 38-year-old woman with a complete hydatidiform mole and multiple uterine fibroids underwent a failed attempt at suction aspiration.
  • Following treatment with methotrexate, a nonmetastatic persistent trophoblastic tumour developed.
  • Conclusion. We propose that primary treatment of molar pregnancies with chemotherapy is a useful treatment option in cases where uterine abnormalities interfere with suction aspiration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1740-8 [8929267.001]
  • [Cites] Br J Obstet Gynaecol. 1994 Jul;101(7):637-8 [8043548.001]
  • [Cites] Am J Obstet Gynecol. 1988 Jun;158(6 Pt 1):1299-306 [3381858.001]
  • [Cites] Lancet Oncol. 2003 Nov;4(11):670-8 [14602247.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):309-12 [10985885.001]
  • (PMID = 19707478.001).
  • [ISSN] 1687-9627
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2729468
  •  go-up   go-down


89. Lok CA, Zürcher AF, van der Velden J: A case of a hydatidiform mole in a 56-year-old woman. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):163-6
Hazardous Substances Data Bank. METHIMAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a hydatidiform mole in a 56-year-old woman.
  • A case of a 56-year-old woman with a mole pregnancy and a human chorionic gonadotropin (HCG)-induced thyreotoxicosis is presented.
  • Thyroid function normalized with thiamazol treatment.
  • The literature on risk factors for developing persistent GTD and the possibilities for treatment in older patients is reviewed.
  • [MeSH-major] Hydatidiform Mole / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Age Factors. Antithyroid Agents / therapeutic use. Female. Humans. Hysterectomy. Methimazole / therapeutic use. Middle Aged. Pregnancy. Thyrotoxicosis / drug therapy. Thyrotoxicosis / etiology

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670312.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antithyroid Agents; 554Z48XN5E / Methimazole
  • [Number-of-references] 18
  •  go-up   go-down


90. Gonzalez D, Elizondo BJ, Haslag S, Buchanan G, Burdick JS, Guzzetta PC, Hicks BA, Andersen JM: Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome. J Pediatr Gastroenterol Nutr; 2001 Aug;33(2):183-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome.
  • BACKGROUND: A patient affected by blue rubber-bleb nevus syndrome had chronic gastrointestinal bleeding requiring weekly blood transfusions.
  • METHODS: Octreotide therapy, 5.7 microg/kg subcutaneously twice daily, was initiated, and the patient was followed up clinically.
  • Complete blood counts, blood glucose concentration, pancreatic enzyme concentration, liver function tests, and growth hormone concentration were monitored during treatments.
  • RESULTS: During the 4 weeks after initiation of octreotide therapy, hemoglobin concentration was maintained without the need for transfusions.
  • [MeSH-major] Gastrointestinal Hemorrhage / drug therapy. Gastrointestinal Hemorrhage / etiology. Nevus, Blue / complications. Octreotide / therapeutic use. Skin Neoplasms / complications
  • [MeSH-minor] Anemia, Iron-Deficiency. Blood Transfusion. Child. Female. Gastrointestinal Agents / therapeutic use. Humans. Intestine, Small / pathology. Syndrome. Treatment Outcome. Veins / abnormalities

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Blue Rubber Bleb Nevus.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568521.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrointestinal Agents; RWM8CCW8GP / Octreotide
  •  go-up   go-down


91. Amezcua CA, Bahador A, Naidu YM, Felix JC: Expression of human telomerase reverse transcriptase, the catalytic subunit of telomerase, is associated with the development of persistent disease in complete hydatidiform moles. Am J Obstet Gynecol; 2001 Jun;184(7):1441-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of human telomerase reverse transcriptase, the catalytic subunit of telomerase, is associated with the development of persistent disease in complete hydatidiform moles.
  • OBJECTIVE: This study was undertaken to determine the putative role of telomerase activity and human telomerase reverse transcriptase (hTERT) expression in the development of persistent disease in patients with a diagnosis of complete hydatidiform mole.
  • The role of telomerase in the pathogenesis of complete hydatidiform moles is not clearly understood.
  • STUDY DESIGN: Telomerase activity and hTERT expression were analyzed in the initial uterine evacuation specimen of 54 complete hydatidiform moles by use of the telomeric repeat amplification protocol assay and reverse transcription-polymerase chain reaction methods.
  • RESULTS: Among the 54 patients who were examined with a diagnosis of complete hydatidiform mole, persistent trophoblastic disease requiring postevacuation chemotherapy developed in 6.
  • Both telomerase activity and hTERT expression were detected in all 6 cases of persistent disease on the initial molar tissue sampled.
  • Among the 48 nonpersistent moles, telomerase activity was detected in 29 (60%) and hTERT expression was demonstrated in 26 (54%).
  • The detection of hTERT expression was significantly associated with the presence of persistent disease (P =.035).
  • Moreover, the absence of hTERT expression in molar tissue obtained from uterine evacuation demonstrated a 100% negative predictability in determining cases of complete mole that were nonpersistent.
  • CONCLUSIONS: Compared with telomerase activity, the expression of hTERT is significantly associated with the development of persistent disease in complete hydatidiform moles.
  • The absence of hTERT expression in the initial tissue sample from complete moles may have potential clinical value in determining patients who will eventually undergo spontaneous remission after uterine evacuation.
  • [MeSH-major] Hydatidiform Mole / enzymology. RNA. Telomerase / metabolism. Uterine Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11408866.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / telomerase RNA; 63231-63-0 / RNA; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


92. Knoeller S, Lim E, Aleta L, Hertwig K, Dudenhausen JW, Arck PC: Distribution of immunocompetent cells in decidua of controlled and uncontrolled (choriocarcinoma/hydatidiform mole) trophoblast invasion. Am J Reprod Immunol; 2003 Jul;50(1):41-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of immunocompetent cells in decidua of controlled and uncontrolled (choriocarcinoma/hydatidiform mole) trophoblast invasion.
  • PROBLEM: Pregnancy has been considered as a model of successfully controlled tissue invasion where trophoblast cells infiltrate the maternal decidua without being rejected or without destroying the tissue.
  • In choriocarcinoma (CC) and hydatidiform mole (HM), a dysregulation of invasive (malignant/benign) trophoblast cells is present.
  • METHODS: Immunocompetent cells were detected by immunohistochemistry in decidual tissue from first trimester NP (n = 10), CC (n = 12) and HM (n = 11) using antibodies against CD8+, CD3+, CD56+, CD68+ cell surface markers and mast cell tryptase (MCT).
  • The number of CD68 positive cells (macrophages) were not significantly different among the tissue pools.
  • [MeSH-major] Choriocarcinoma / pathology. Decidua / pathology. Hydatidiform Mole / pathology. Leukocytes / pathology

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14506927.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD56; 0 / Antigens, CD8; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


93. Tica AA, Tica OS, Georgescu CV, Mixich F, Tica VJ, Berceanu S, Ebanca E, Patrascu A, Simionescu C: Recurrent partial hydatidiform mole, with a first twin pregnancy, after treatment with clomiphene citrate. Gynecol Endocrinol; 2009 Aug;25(8):514-9
Hazardous Substances Data Bank. CLOMIPHENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent partial hydatidiform mole, with a first twin pregnancy, after treatment with clomiphene citrate.
  • This treatment resulted in a twin pregnancy, one degenerated into a partial hydatidiform mole and the other into a very early embryo death.
  • Despite all medical advice, she returned 8 months later with a new pregnancy, which proved to be a new partial hydatidiform mole, this time a single one.
  • As all the three pregnancies obtained after treatment with clomiphene were abnormal, two being partial hydatidiform moles and one being a premature miscarriage, without any genetic aberrations of the genitors, it seems very possible that clomiphene, apart from improving fertility, also increases the risk of abnormal ovum appearance.
  • [MeSH-major] Clomiphene / adverse effects. Fertility Agents, Female / adverse effects. Hydatidiform Mole / chemically induced. Pregnancy, Multiple. Twins. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Abortion, Spontaneous / chemically induced. Adult. Embryo Loss / chemically induced. Female. Humans. Infertility, Female / drug therapy. Karyotyping. Luteoma / ultrasonography. Ovarian Neoplasms / ultrasonography. Pregnancy. Recurrence. Ultrasonography, Prenatal

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499414.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fertility Agents, Female; 1HRS458QU2 / Clomiphene
  •  go-up   go-down


94. Sato K, Sakakibara N, Hasegawa K, Minami H, Tsuji T: A preliminary report of the treatment of blue nevus with dermal injection of riboflavin and exposure to near-ultraviolet/visible radiation (ribophototherapy). J Dermatol Sci; 2000 May;23(1):22-6
Hazardous Substances Data Bank. Riboflavin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary report of the treatment of blue nevus with dermal injection of riboflavin and exposure to near-ultraviolet/visible radiation (ribophototherapy).
  • Dye lasers are useful for treating pigmented skin lesions, but their equipment is expensive and bulky.
  • A simple and cheap phototherapy would be acceptable to dermatologists for treating pigmented skin lesions such as nevus of Ota.
  • We investigated as a pilot study whether dermal injection of riboflavin and exposure to near-ultraviolet/visible radiation (ribophototherapy) decreases the dermal pigment of blue nevi which are recalcitrant to laser therapy.
  • The therapeutic efficacy was assessed by comparison of the amount of dermal pigment in hematoxylin-eosin specimens taken before and after treatment.
  • Pigmentation of the nevus became faint to the depth of 1 mm with little noticeable epidermal change after 21 treatments.
  • Ribophototherapy is hopeful for treating pigmented skin lesions.
  • [MeSH-major] Nevus, Blue / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage. Riboflavin / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans. Injections, Intradermal. Male. Microscopy, Electron. Skin Pigmentation / drug effects. Skin Pigmentation / radiation effects. Ultraviolet Therapy

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10699761.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Photosensitizing Agents; TLM2976OFR / Riboflavin
  •  go-up   go-down


95. Ulkur E, Celikoz B, Yuksel F, Karagoz H: Carbon dioxide laser therapy for an inflammatory linear verrucous epidermal nevus: a case report. Aesthetic Plast Surg; 2004 Nov-Dec;28(6):428-30
Hazardous Substances Data Bank. Povidone-iodine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon dioxide laser therapy for an inflammatory linear verrucous epidermal nevus: a case report.
  • The treatment of an inflammatory linear verrucous epidermal nevus (ILVEN), an uncommon type of epidermal nevus, is still controversial.
  • The use of laser therapy is a recently reported method.
  • Although various results have been reported with the use of the laser in the treatment epidermal nevis, the authors have not seen any report on the use of the carbon dioxide laser in ILVEN treatment.
  • [MeSH-major] Carbon Dioxide / administration & dosage. Inflammation / complications. Laser Therapy / methods. Nevus, Pigmented / complications. Nevus, Pigmented / surgery
  • [MeSH-minor] Adult. Anti-Infective Agents, Local / therapeutic use. Epidermis / pathology. Histamine H1 Antagonists / therapeutic use. Humans. Hyperplasia / pathology. Male. Povidone-Iodine / therapeutic use. Pruritus / drug therapy. Pruritus / etiology. Reconstructive Surgical Procedures / methods

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Verrucous nevus.
  • Genetic Alliance. consumer health - Epidermal nevus.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583849.001).
  • [ISSN] 0364-216X
  • [Journal-full-title] Aesthetic plastic surgery
  • [ISO-abbreviation] Aesthetic Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Histamine H1 Antagonists; 142M471B3J / Carbon Dioxide; 25655-41-8 / Povidone-Iodine
  •  go-up   go-down


96. Steigrad SJ, Robertson G, Kaye AL: Serial hCG and ultrasound measurements for predicting malignant potential in multiple pregnancies associated with complete hydatidiform mole: a report of 2 cases. J Reprod Med; 2004 Jul;49(7):554-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial hCG and ultrasound measurements for predicting malignant potential in multiple pregnancies associated with complete hydatidiform mole: a report of 2 cases.
  • BACKGROUND: Multiple pregnancy complicated by the presence of a complete hydatidiform mole (CHM) is a rare clinical entity.
  • The patient was treated with single-agent chemotherapy, with complete resolution.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / blood. Hydatidiform Mole / ultrasonography. Pregnancy Complications, Neoplastic / ultrasonography. Pregnancy, Multiple. Uterine Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15305827.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


97. von Moos R, Schaffner R, Cathomas R, Grimm B: Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication. J Immunother; 2010 Jan;33(1):92-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication.
  • Malignant blue nevi are a rare variant of cutaneous melanoma often associated with metastatic disease and poor prognosis.
  • Information on the treatment of this condition is limited.
  • This case study reports the use of intralesional interferon -alpha2b (IFN-alpha2b) as a salvage option in a male patient with a congenital blue nevus on the right buttock.
  • After initial diagnosis, the primary lesion (lesion 1) was partially resected and the patient received aggressive treatment with radiotherapy and concomitant polychemotherapy (cisplatin, vinblastine, and dacarbazine).
  • Although this treatment stabilized the primary lesion, at cycle 6, the patient developed a measurable locoregional metastasis (lesion 2).
  • At this stage, the patient was treated with intralesional IFN-alpha2b twice weekly at lesion 2, followed by weekly intralesional IFN-alpha2b therapy to both lesions, which resulted in partial disease regression.
  • Biweekly maintenance therapy with IFN-alpha2b administered to both lesions maintained a partial response (ongoing at 23+ mo) and allowed complete occupational rehabilitation.
  • Thus, intralesional therapy with IFN-alpha2b may be a viable treatment option in patients with locally advanced melanoma who have progressed on prior radiotherapy, polychemotherapy, and/or multikinase antiangiogenic-based therapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Interferon-alpha / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Nevus, Blue / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952952.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


98. Micali G, De Pasquale R, Caltabiano R, Impallomeni R, Lacarrubba F: Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatolog Treat; 2002 Sep;13(3):123-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report.
  • BACKGROUND: Imiquimod 5% cream has been shown to be effective in the treatment of superficial basal cell carcinomas (sBCCs).
  • OBJECTIVE: To evaluate the efficacy, safety and compliance of imiquimod 5% cream for the treatment of sBCCs and nodular BCCs (nBCCs) in patients affected by basal cell nevus syndrome.
  • Treatment consisted for sBCCs of three weekly applications and for nBCCs of five weekly applications for 8 weeks.
  • RESULTS: Three sBCCs cleared clinically after 4 weeks of treatment and two nBCCs after 8 weeks.
  • Local adverse effects (itching, erythema and bleeding) were mild and did not prompt discontinuation of treatment.
  • CONCLUSIONS: Imiquimod 5% cream is an effective therapeutic option for both sBCC and nBCC in patients with basal cell nevus syndrome.
  • The treatment was very well received by all patients engaged in the study, who stated their appreciation for a topical treatment rather than multiple surgical excisions.
  • A higher number of applications and longer treatment periods are required for nBCCs.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Basal Cell Nevus Syndrome / drug therapy. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12227875.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


99. Kagy MK, Amonette R: The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg; 2000 Jun;26(6):577-8; discussion 578-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.
  • OBJECTIVE: The purpose of this study is to examine the effectiveness, tolerability, and desirability of imiquimod 5% cream in treating superficial non-facial basal cell carcinomas in a patient with basal cell nevus syndrome.
  • Our patient reported that he tolerated the treatment but he would not desire this treatment again based on the length of treatment time and the degree of local inflammation at the treatment sites.
  • The degree of local inflammatory response may affect the patients' tolerability of treatment and therefore patient compliance.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / drug therapy. Interferon Inducers / administration & dosage. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10848940.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Interferon Inducers; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


100. Uberti EM, Fajardo Mdo C, da Cunha AG, Rosa MW, Ayub AC, Graudenz Mda S, Schmid H: Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment. Gynecol Oncol; 2009 Aug;114(2):299-305
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment.
  • OBJECTIVE: To evaluate the efficacy of actinomycin D (Act-D) as prophylactic chemotherapy (P-Chem) to reduce postmolar gestational trophoblastic neoplasia (GTN) in patients with high-risk hydatidiform mole (Hr-HM).
  • From 1996 to 2006, 163 received a single bolus dose of Act-D at time of uterine evacuation (Hr-HM-chem group); 102 with the same risk factors did not get P-Chem (Hr-HM-control group).
  • Variables were: number of patients with postmolar GTN who required chemotherapy during follow-up, postmolar GTN morbidity, compliance and operational costs.
  • Treatment costs and emotional complications were reduced.
  • This prophylactic approach can be adopted before uterine evacuation in any TDC that treats Hr-HM patients that present with undelivered moles.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dactinomycin / therapeutic use. Gestational Trophoblastic Disease / prevention & control. Hydatidiform Mole / drug therapy

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427681.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down






Advertisement